,coef,coef_graph,coef_combined,coef_combined_zscore,coef_combined2
5-Phosphoribose 1-diphosphate biosynthesis,1.6046454e-06,2.0,1.6046454e-06,-0.074651375,0.34984922
A tetrasaccharide linker sequence is required for GAG synthesis,0.0010259374,8.0,0.0010259374,0.5235266,0.52287114
ABC transporters in lipid homeostasis,0.00022685189,9.0,0.00022685189,0.05688591,0.12838835
ADP signalling through P2Y purinoceptor 1,7.377107e-08,14.0,7.377107e-08,-0.07554535,-0.19901504
ADP signalling through P2Y purinoceptor 12,3.5942044e-08,13.0,3.5942044e-08,-0.07556744,-0.15334854
AKT phosphorylates targets in the cytosol,1.7864927e-06,13.0,1.7864927e-06,-0.074545175,-0.15258442
AKT phosphorylates targets in the nucleus,6.548458e-08,8.0,6.548458e-08,-0.07555019,0.07507938
AKT-mediated inactivation of FOXO1A,2.0529074e-08,4.0,2.0529074e-08,-0.07557644,0.25779173
ALKBH2 mediated reversal of alkylation damage,0.0,2.0,0.0,-0.075588435,0.3491488
ALKBH3 mediated reversal of alkylation damage,2.1206948e-07,3.0,2.1206948e-07,-0.07546459,0.30355835
AMPK inhibits chREBP transcriptional activation activity,8.038889e-08,6.0,8.038889e-08,-0.07554149,0.16645189
APC truncation mutants are not K63 polyubiquitinated,0.0,1.0,0.0,-0.075588435,0.39483184
APC truncation mutants have impaired AXIN binding,3.588172e-08,10.0,3.588172e-08,-0.07556748,-0.016299551
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1,7.7165146e-07,42.0,7.7165146e-07,-0.07513782,-1.4778345
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway,1.5619049e-05,6.0,1.5619049e-05,-0.0664674,0.17323449
APOBEC3G mediated resistance to HIV-1 infection,2.0539657e-07,4.0,2.0539657e-07,-0.07546849,0.25787243
ARL13B-mediated ciliary trafficking of INPP5E,4.538544e-05,3.0,4.538544e-05,-0.049084764,0.3232765
ATF4 activates genes,8.304592e-07,2.0,8.304592e-07,-0.07510347,0.3495113
ATF6 (ATF6-alpha) activates chaperone genes,3.477096e-05,6.0,3.477096e-05,-0.05528329,0.18159427
ATP sensitive Potassium channels,1.0131745e-06,2.0,1.0131745e-06,-0.07499677,0.34959105
AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00036881084,32.0,0.00036881084,0.13978545,-0.86035573
AURKA Activation by TPX2,9.1365297e-07,48.0,9.1365297e-07,-0.075054884,-1.7518704
AXIN missense mutants destabilize the destruction complex,6.835245e-08,10.0,6.835245e-08,-0.075548515,-0.01628538
Abacavir metabolism,2.053238e-05,3.0,2.053238e-05,-0.06359817,0.31242815
Abacavir transmembrane transport,0.0,1.0,0.0,-0.075588435,0.39483184
Abasic sugar-phosphate removal via the single-nucleotide replacement pathway,4.868091e-09,2.0,4.868091e-09,-0.07558559,0.34915096
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,4.6281805e-11,2.0,4.6281805e-11,-0.075588405,0.3491488
Acetylation,0.0,1.0,0.0,-0.075588435,0.39483184
Acetylcholine Neurotransmitter Release Cycle,3.9615347e-06,6.0,3.9615347e-06,-0.073275015,0.16814598
Acetylcholine regulates insulin secretion,2.6777053e-07,6.0,2.6777053e-07,-0.07543206,0.16653368
Acrosome Reaction,0.0,1.0,0.0,-0.075588435,0.39483184
Activated NOTCH1 Transmits Signal to the Nucleus,2.1439243e-08,20.0,2.1439243e-08,-0.07557592,-0.4731359
Activated NTRK2 signals through CDK5,2.6121365e-09,5.0,2.6121365e-09,-0.0755869,0.21210094
Activated NTRK2 signals through FRS2 and FRS3,3.6669224e-08,7.0,3.6669224e-08,-0.075567015,0.120749794
Activated NTRK2 signals through FYN,5.786863e-09,5.0,5.786863e-09,-0.07558505,0.21210232
Activated NTRK2 signals through PI3K,2.2419005e-08,4.0,2.2419005e-08,-0.07557534,0.2577926
Activated NTRK2 signals through PLCG1,1.5120876e-09,2.0,1.5120876e-09,-0.07558755,0.34914947
Activated NTRK2 signals through RAS,6.4697653e-10,5.0,6.4697653e-10,-0.075588055,0.21210007
Activated NTRK3 signals through PI3K,1.6521726e-07,5.0,1.6521726e-07,-0.07549195,0.21217191
Activated NTRK3 signals through PLCG1,2.7393583e-09,2.0,2.7393583e-09,-0.07558683,0.34915
Activated NTRK3 signals through RAS,8.886792e-09,5.0,8.886792e-09,-0.07558324,0.21210368
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,9.696297e-06,11.0,9.696297e-06,-0.0699261,-0.0577658
Activation and oligomerization of BAK protein,3.7129233e-08,3.0,3.7129233e-08,-0.07556675,0.303482
Activation of AMPA receptors,0.0,1.0,0.0,-0.075588435,0.39483184
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins,2.7495873e-06,43.0,2.7495873e-06,-0.07398276,-1.522654
Activation of ATR in response to replication stress,3.720979e-06,22.0,3.720979e-06,-0.073415495,-0.562887
Activation of BAD and translocation to mitochondria ,1.0249731e-06,10.0,1.0249731e-06,-0.07498988,-0.015867814
Activation of BIM and translocation to mitochondria ,1.731679e-06,3.0,1.731679e-06,-0.07457719,0.30422166
Activation of BMF and translocation to mitochondria,1.0942196e-06,4.0,1.0942196e-06,-0.07494944,0.2582604
Activation of C3 and C5,0.0,1.0,0.0,-0.075588435,0.39483184
Activation of DNA fragmentation factor,1.4463996e-06,8.0,1.4463996e-06,-0.07474378,0.07568215
Activation of G protein gated Potassium channels,9.2973045e-07,10.0,9.2973045e-07,-0.075045496,-0.015909387
Activation of Matrix Metalloproteinases,4.469758e-08,6.0,4.469758e-08,-0.07556233,0.1664363
Activation of NF-kappaB in B cells,0.0006348457,46.0,0.0006348457,0.29514143,-1.3837941
Activation of NOXA and translocation to mitochondria,7.4049503e-06,4.0,7.4049503e-06,-0.07126417,0.26101503
Activation of Nicotinic Acetylcholine Receptors,1.5371375e-05,4.0,1.5371375e-05,-0.066612035,0.26449236
Activation of PPARGC1A (PGC-1alpha) by phosphorylation,3.780493e-07,6.0,3.780493e-07,-0.07536767,0.1665818
Activation of PUMA and translocation to mitochondria,3.8181447e-06,6.0,3.8181447e-06,-0.07335876,0.16808341
Activation of RAC1,3.504248e-08,5.0,3.504248e-08,-0.07556797,0.2121151
Activation of RAS in B cells,4.105885e-05,5.0,4.105885e-05,-0.051611356,0.23002192
Activation of SMO,3.8143114e-06,4.0,3.8143114e-06,-0.073361,0.25944772
Activation of TRKA receptors,2.2230313e-06,2.0,2.2230313e-06,-0.074290246,0.35011917
Activation of anterior HOX genes in hindbrain development during early embryogenesis,8.897801e-05,44.0,8.897801e-05,-0.02362808,-1.5306985
Activation of gene expression by SREBF (SREBP),4.1760645e-06,17.0,4.1760645e-06,-0.07314974,-0.3342734
Activation of the TFAP2 (AP-2) family of transcription factors,9.459939e-06,4.0,9.459939e-06,-0.07006413,0.26191205
"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S",2.0950154e-05,31.0,2.0950154e-05,-0.0633542,-0.9665135
Activation of the pre-replicative complex,5.711963e-05,22.0,5.711963e-05,-0.042232372,-0.5395786
"Activation, myristolyation of BID and translocation to mitochondria",2.0956336e-06,4.0,2.0956336e-06,-0.07436465,0.2586975
"Activation, translocation and oligomerization of BAX",5.661718e-07,3.0,5.661718e-07,-0.07525781,0.30371293
Acyl chain remodeling of CL,2.9471203e-06,6.0,2.9471203e-06,-0.0738674,0.16770321
Acyl chain remodeling of DAG and TAG,9.664991e-07,4.0,9.664991e-07,-0.07502403,0.25820464
Acyl chain remodelling of PC,1.8326097e-06,9.0,1.8326097e-06,-0.07451825,0.030167721
Acyl chain remodelling of PE,8.740968e-07,8.0,8.740968e-07,-0.07507799,0.07543234
Acyl chain remodelling of PG,3.917203e-06,4.0,3.917203e-06,-0.07330091,0.25949264
Acyl chain remodelling of PI,4.2701603e-07,4.0,4.2701603e-07,-0.07533907,0.25796917
Acyl chain remodelling of PS,8.481285e-07,4.0,8.481285e-07,-0.07509315,0.258153
Adrenaline signalling through Alpha-2 adrenergic receptor,2.099818e-11,2.0,2.099818e-11,-0.07558843,0.3491488
"Adrenaline,noradrenaline inhibits insulin secretion",2.5330058e-09,14.0,2.5330058e-09,-0.07558695,-0.19904612
Advanced glycosylation endproduct receptor signaling,1.1042008e-06,10.0,1.1042008e-06,-0.07494362,-0.015833234
Aflatoxin activation and detoxification,4.1248763e-06,6.0,4.1248763e-06,-0.07317964,0.16821729
Agmatine biosynthesis,0.0,1.0,0.0,-0.075588435,0.39483184
Alpha-defensins,2.267771e-06,2.0,2.267771e-06,-0.074264124,0.3501387
Alpha-oxidation of phytanate,2.0297362e-08,6.0,2.0297362e-08,-0.07557658,0.16642566
Alternative complement activation,1.0208693e-05,2.0,1.0208693e-05,-0.069626875,0.3536049
Amine ligand-binding receptors,5.7677e-10,5.0,5.7677e-10,-0.07558809,0.21210006
Amino acid transport across the plasma membrane,3.8063965e-09,11.0,3.8063965e-09,-0.07558621,-0.061996553
Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal,9.143609e-06,52.0,9.143609e-06,-0.07024886,-1.9310101
Amyloid fiber formation,0.0021149572,28.0,0.0021149572,1.1594799,0.08456688
Anchoring fibril formation,0.0,1.0,0.0,-0.075588435,0.39483184
Anchoring of the basal body to the plasma membrane,3.4554225e-06,63.0,3.4554225e-06,-0.07357057,-2.4360058
Androgen biosynthesis,6.7892323e-09,2.0,6.7892323e-09,-0.075584464,0.34915176
Antagonism of Activin by Follistatin,2.1434426e-08,3.0,2.1434426e-08,-0.07557592,0.30347517
"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",1.6301066e-06,18.0,1.6301066e-06,-0.074636504,-0.3810677
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,5.375482e-05,21.0,5.375482e-05,-0.044197313,-0.49536434
Antigen processing: Ubiquitination & Proteasome degradation,0.011544523,179.0,6.449454e-05,-0.037925657,-2.6975734
Apoptotic cleavage of cell adhesion  proteins,1.5250553e-08,4.0,1.5250553e-08,-0.075579524,0.25778946
Arachidonate production from DAG,6.1446785e-09,4.0,6.1446785e-09,-0.075584844,0.25778547
Aryl hydrocarbon receptor signalling,1.8593753e-05,6.0,1.8593753e-05,-0.064730264,0.17453295
Assembly of active LPL and LIPC lipase complexes,5.2398373e-06,8.0,5.2398373e-06,-0.07252853,0.07733798
Assembly of the ORC complex at the origin of replication,0.00017661824,6.0,0.00017661824,0.027551046,0.24351041
Association of TriC/CCT with target proteins during biosynthesis,2.3669638e-05,28.0,2.3669638e-05,-0.06176611,-0.82827747
Astrocytic Glutamate-Glutamine Uptake And Metabolism,1.036635e-08,4.0,1.036635e-08,-0.075582385,0.2577873
Asymmetric localization of PCP proteins,3.5999324e-08,39.0,3.5999324e-08,-0.07556741,-1.3411065
Attachment of GPI anchor to uPAR,5.911174e-07,5.0,5.911174e-07,-0.07524324,0.2123578
Attenuation phase,4.3962624e-05,12.0,4.3962624e-05,-0.04991565,-0.08849159
Autodegradation of Cdh1 by Cdh1:APC/C,5.3003583e-07,41.0,5.3003583e-07,-0.07527891,-1.4322568
Axonal growth inhibition (RHOA activation),3.8171653e-08,5.0,3.8171653e-08,-0.07556614,0.21211645
Axonal growth stimulation,2.3898338e-08,4.0,2.3898338e-08,-0.07557448,0.25779322
B-WICH complex positively regulates rRNA expression,0.01542197,25.0,0.01542197,8.930355,6.03011
BBSome-mediated cargo-targeting to cilium,1.179805e-07,8.0,1.179805e-07,-0.07551953,0.0751023
BDNF activates NTRK2 (TRKB) signaling,0.0,1.0,0.0,-0.075588435,0.39483184
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,1.6245636e-07,5.0,1.6245636e-07,-0.07549356,0.2121707
"BMAL1:CLOCK,NPAS2 activates circadian gene expression",1.6009655e-05,5.0,1.6009655e-05,-0.0662393,0.21908799
Basigin interactions,0.0010560768,9.0,0.0010560768,0.54112715,0.49034396
Beta defensins,1.0228858e-05,5.0,1.0228858e-05,-0.0696151,0.21656467
Beta-catenin phosphorylation cascade,4.8798e-05,11.0,4.8798e-05,-0.047091942,-0.040697955
Beta-oxidation of pristanoyl-CoA,8.0104755e-06,5.0,8.0104755e-06,-0.070910566,0.21559636
Beta-oxidation of very long chain fatty acids,6.2530717e-06,8.0,6.2530717e-06,-0.07193683,0.077780254
Bicarbonate transporters,1.5632085e-07,3.0,1.5632085e-07,-0.07549715,0.30353403
Binding of TCF/LEF:CTNNB1 to target gene promoters,8.4025646e-07,7.0,8.4025646e-07,-0.07509775,0.12110056
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB,0.0,1.0,0.0,-0.075588435,0.39483184
"Biosynthesis of A2E, implicated in retinal degradation",2.7473453e-07,2.0,2.7473453e-07,-0.075427994,0.34926873
Biosynthesis of D-series resolvins,4.961288e-06,4.0,4.961288e-06,-0.072691195,0.25994837
Biosynthesis of DHA-derived sulfido conjugates,0.0,1.0,0.0,-0.075588435,0.39483184
Biosynthesis of DPAn-3 SPMs,2.4135323e-07,3.0,2.4135323e-07,-0.075447485,0.30357116
Biosynthesis of DPAn-6 SPMs,1.3823245e-07,2.0,1.3823245e-07,-0.07550771,0.34920916
Biosynthesis of E-series 18(R)-resolvins,7.267296e-07,4.0,7.267296e-07,-0.07516405,0.2581
Biosynthesis of E-series 18(S)-resolvins,2.1847638e-06,4.0,2.1847638e-06,-0.0743126,0.25873643
Biosynthesis of aspirin-triggered D-series resolvins,3.5377872e-07,4.0,3.5377872e-07,-0.07538184,0.2579372
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives,1.2129721e-10,2.0,1.2129721e-10,-0.07558837,0.34914887
Biosynthesis of maresins,4.204358e-07,2.0,4.204358e-07,-0.075342916,0.34933233
Biosynthesis of protectins,1.1319419e-12,2.0,1.1319419e-12,-0.075588435,0.3491488
Biotin transport and metabolism,2.9399282e-06,11.0,2.9399282e-06,-0.07387161,-0.06071495
Breakdown of the nuclear lamina,1.0427206e-08,3.0,1.0427206e-08,-0.07558234,0.30347037
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,4.954668e-06,13.0,4.954668e-06,-0.07269506,-0.15120153
Butyrophilin (BTN) family interactions,1.772431e-06,7.0,1.772431e-06,-0.074553385,0.121507466
C6 deamination of adenosine,1.5776763e-07,2.0,1.5776763e-07,-0.0754963,0.34921765
CASP8 activity is inhibited,6.5409654e-06,9.0,6.5409654e-06,-0.071768716,0.032222915
CD209 (DC-SIGN) signaling,3.133643e-08,15.0,3.133643e-08,-0.07557014,-0.24471657
CD22 mediated BCR regulation,0.0023610604,5.0,0.0023610604,1.3031963,1.2426997
CD28 dependent PI3K/Akt signaling,3.0368838e-06,13.0,3.0368838e-06,-0.07381499,-0.15203863
CD28 dependent Vav1 pathway,4.219013e-05,9.0,4.219013e-05,-0.050950725,0.047783725
CDC6 association with the ORC:origin complex,4.7494952e-05,7.0,4.7494952e-05,-0.04785288,0.14146529
CDK-mediated phosphorylation and removal of Cdc6,5.045129e-07,44.0,5.045129e-07,-0.07529381,-1.569317
CDO in myogenesis,4.5129777e-06,18.0,4.5129777e-06,-0.072953,-0.37980935
CDT1 association with the CDC6:ORC:origin complex,0.00030828713,36.0,0.00030828713,0.10444152,-1.0695063
CHL1 interactions,2.8058604e-09,4.0,2.8058604e-09,-0.075586796,0.257784
CLEC7A (Dectin-1) induces NFAT activation,1.2964341e-05,7.0,1.2964341e-05,-0.06801766,0.1263927
CLEC7A/inflammasome pathway,4.271047e-07,3.0,4.271047e-07,-0.07533902,0.30365223
COPI-dependent Golgi-to-ER retrograde traffic,1.2371339e-06,41.0,1.2371339e-06,-0.07486599,-1.4319483
COPI-independent Golgi-to-ER retrograde traffic,1.0728907e-07,25.0,1.0728907e-07,-0.075525776,-0.7015134
COPI-mediated anterograde transport,8.227349e-05,59.0,8.227349e-05,-0.027543312,-2.2188702
COPII-mediated vesicle transport,1.4277503e-05,51.0,1.4277503e-05,-0.06725082,-1.8830862
COX reactions,5.798144e-07,2.0,5.798144e-07,-0.075249836,0.34940192
CREB3 factors activate genes,4.5135035e-05,5.0,4.5135035e-05,-0.049230997,0.23180118
CRMPs in Sema3A signaling,4.1000094e-05,7.0,4.1000094e-05,-0.05164567,0.13863029
CS/DS degradation,2.788545e-05,7.0,2.788545e-05,-0.05930421,0.13290577
CTLA4 inhibitory signaling,0.00050846994,15.0,0.00050846994,0.22134197,-0.022783749
Ca2+ activated K+ channels,1.3112322e-07,3.0,1.3112322e-07,-0.07551186,0.30352303
Ca2+ pathway,0.00010796217,35.0,0.00010796217,-0.012541931,-1.1112648
Calcineurin activates NFAT,2.0630287e-05,7.0,2.0630287e-05,-0.063540995,0.1297389
Calcitonin-like ligand receptors,0.0,1.0,0.0,-0.075588435,0.39483184
Calmodulin induced events,2.7263036e-07,9.0,2.7263036e-07,-0.07542922,0.029486792
Calnexin/calreticulin cycle,4.7011086e-05,19.0,4.7011086e-05,-0.048135445,-0.40694195
Carboxyterminal post-translational modifications of tubulin,2.8730602e-08,13.0,2.8730602e-08,-0.075571656,-0.15335168
Cargo concentration in the ER,2.6747787e-07,19.0,2.6747787e-07,-0.07543223,-0.42734548
Cargo recognition for clathrin-mediated endocytosis,0.0002855477,60.0,0.0002855477,0.091162406,-2.1758242
Carnitine synthesis,1.8127691e-10,4.0,1.8127691e-10,-0.07558833,0.25778288
Caspase-mediated cleavage of cytoskeletal proteins,8.4055023e-07,11.0,8.4055023e-07,-0.075097576,-0.06163132
Catecholamine biosynthesis,0.0,1.0,0.0,-0.075588435,0.39483184
Cation-coupled Chloride cotransporters,1.5644764e-07,3.0,1.5644764e-07,-0.07549707,0.3035341
Cell redox homeostasis,0.0,1.0,0.0,-0.075588435,0.39483184
Cellular hexose transport,7.242111e-06,8.0,7.242111e-06,-0.07135927,0.07821197
Centrosome maturation,2.3433726e-05,54.0,2.3433726e-05,-0.061903875,-2.0161386
Ceramide signalling,4.5746482e-08,2.0,4.5746482e-08,-0.07556172,0.3491688
ChREBP activates metabolic gene expression,3.2087783e-08,5.0,3.2087783e-08,-0.0755697,0.2121138
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex,7.815249e-08,6.0,7.815249e-08,-0.07554279,0.1664509
Cholesterol biosynthesis via desmosterol,3.4877314e-09,2.0,3.4877314e-09,-0.07558639,0.34915033
Cholesterol biosynthesis via lathosterol,1.6379568e-11,2.0,1.6379568e-11,-0.07558843,0.3491488
Choline catabolism,2.2210356e-09,2.0,2.2210356e-09,-0.07558713,0.34914976
Chondroitin sulfate biosynthesis,0.00031849215,11.0,0.00031849215,0.11040093,0.0770232
Chylomicron assembly,8.9943764e-13,2.0,8.9943764e-13,-0.075588435,0.3491488
Chylomicron clearance,4.9807824e-08,2.0,4.9807824e-08,-0.07555935,0.34917057
Chylomicron remodeling,8.7284645e-11,3.0,8.7284645e-11,-0.07558838,0.30346584
Citric acid cycle (TCA cycle),1.5602942e-06,19.0,1.5602942e-06,-0.074677266,-0.42678112
Class C/3 (Metabotropic glutamate/pheromone receptors),4.811408e-09,4.0,4.811408e-09,-0.07558562,0.25778487
Classical Kir channels,1.6615155e-05,2.0,1.6615155e-05,-0.06588571,0.35640132
Cleavage of Growing Transcript in the Termination Region ,9.0111695e-05,50.0,9.0111695e-05,-0.022966046,-1.8043017
Cleavage of the damaged purine,2.6114704e-11,2.0,2.6114704e-11,-0.07558841,0.3491488
Cleavage of the damaged pyrimidine ,1.7876348e-08,8.0,1.7876348e-08,-0.075578,0.075058594
"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.00037735346,9.0,0.00037735346,0.14477408,0.19408207
Coenzyme A biosynthesis,7.92326e-08,4.0,7.92326e-08,-0.07554216,0.2578174
Cohesin Loading onto Chromatin,5.5451505e-06,8.0,5.5451505e-06,-0.07235024,0.07747125
Collagen chain trimerization,4.1411968e-05,9.0,4.1411968e-05,-0.051405147,0.04744406
Collagen degradation,7.536236e-07,11.0,7.536236e-07,-0.07514834,-0.06166926
Common Pathway of Fibrin Clot Formation,6.969886e-08,5.0,6.969886e-08,-0.075547725,0.21213022
Complex I biogenesis,2.120136e-05,24.0,2.120136e-05,-0.06320751,-0.6466229
Condensation of Prometaphase Chromosomes,7.722356e-09,5.0,7.722356e-09,-0.07558392,0.21210316
Condensation of Prophase Chromosomes,5.9504506e-05,13.0,5.9504506e-05,-0.04083968,-0.12739058
Conjugation of carboxylic acids,3.6490536e-07,2.0,3.6490536e-07,-0.07537534,0.3493081
Constitutive Signaling by AKT1 E17K in Cancer,3.4051226e-08,21.0,3.4051226e-08,-0.07556855,-0.5188134
Constitutive Signaling by Aberrant PI3K in Cancer,3.69346e-07,31.0,3.69346e-07,-0.07537275,-0.97549707
Constitutive Signaling by EGFRvIII,2.6952042e-08,13.0,2.6952042e-08,-0.07557269,-0.15335245
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,2.8146424e-06,16.0,2.8146424e-06,-0.07394477,-0.28918466
Constitutive Signaling by NOTCH1 HD Domain Mutants,1.0431899e-08,11.0,1.0431899e-08,-0.07558234,-0.061993662
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,1.202128e-07,40.0,1.202128e-07,-0.07551823,-1.3867527
Constitutive Signaling by NOTCH1 PEST Domain Mutants,6.1187257e-07,40.0,6.1187257e-07,-0.07523111,-1.3865381
Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1.2817303e-08,5.0,1.2817303e-08,-0.07558095,0.2121054
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase,1.1993078e-06,13.0,1.1993078e-06,-0.07488807,-0.15284072
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,2.7849874e-05,21.0,2.7849874e-05,-0.059324984,-0.5066718
Creatine metabolism,5.7348283e-05,5.0,5.7348283e-05,-0.042098846,0.23713225
Creation of C4 and C2 activators,5.7359754e-05,2.0,5.7359754e-05,-0.04209215,0.37418628
Cristae formation,2.6750212e-07,8.0,2.6750212e-07,-0.07543222,0.07516757
Cross-presentation of particulate exogenous antigens (phagosomes),4.731055e-09,4.0,4.731055e-09,-0.07558567,0.25778484
Cross-presentation of soluble exogenous antigens (endosomes),2.3043802e-08,28.0,2.3043802e-08,-0.07557497,-0.83859926
Crosslinking of collagen fibrils,5.7381818e-11,2.0,5.7381818e-11,-0.0755884,0.34914884
Cyclin A/B1/B2 associated events during G2/M transition,9.918916e-07,11.0,9.918916e-07,-0.075009204,-0.061565258
Cyclin D associated events in G1,1.4642293e-05,32.0,1.4642293e-05,-0.0670378,-1.0149499
Cysteine formation from homocysteine,2.388119e-08,3.0,2.388119e-08,-0.07557449,0.3034762
Cytochrome c-mediated apoptotic response,2.4832975e-06,6.0,2.4832975e-06,-0.07413826,0.16750075
Cytosolic iron-sulfur cluster assembly,4.876023e-06,8.0,4.876023e-06,-0.07274099,0.07717917
Cytosolic tRNA aminoacylation,4.5808752e-05,18.0,4.5808752e-05,-0.04883757,-0.3617838
DAP12 signaling,5.2774e-06,21.0,5.2774e-06,-0.0725066,-0.5165247
DCC mediated attractive signaling,7.454624e-06,9.0,7.454624e-06,-0.071235165,0.032621723
DEx/H-box helicases activate type I IFN and inflammatory cytokines production ,6.7582914e-05,7.0,6.7582914e-05,-0.036122143,0.15023366
DNA Damage Recognition in GG-NER,8.6853e-06,21.0,8.6853e-06,-0.0705165,-0.5150371
DNA methylation,0.007735942,9.0,0.007735942,4.4419575,3.4060965
DNA replication initiation,1.8531502e-05,6.0,1.8531502e-05,-0.06476662,0.17450577
DSCAM interactions,1.7011123e-05,7.0,1.7011123e-05,-0.06565447,0.12815914
Deactivation of the beta-catenin transactivating complex,2.1837295e-05,25.0,2.1837295e-05,-0.06283614,-0.6920283
Deadenylation of mRNA,1.925464e-05,16.0,1.925464e-05,-0.06434433,-0.28200862
Dectin-1 mediated noncanonical NF-kB signaling,6.854258e-06,36.0,6.854258e-06,-0.07158576,-1.2010814
Dectin-2 family,1.4191327e-06,8.0,1.4191327e-06,-0.07475971,0.07567025
Defective ABCA1 causes Tangier disease,0.0,1.0,0.0,-0.075588435,0.39483184
Defective ABCA12 causes autosomal recessive congenital ichthyosis type 4B,0.0,1.0,0.0,-0.075588435,0.39483184
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction 3 (SMDP3),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction type 3 (SMDP3),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ABCB11 causes progressive familial intrahepatic cholestasis 2 and benign recurrent intrahepatic cholestasis 2,0.0,1.0,0.0,-0.075588435,0.39483184
"Defective ABCB4 causes progressive familial intrahepatic cholestasis 3, intrahepatic cholestasis of pregnancy 3 and gallbladder disease 1",0.0,1.0,0.0,-0.075588435,0.39483184
Defective ABCB6 causes isolated colobomatous microphthalmia 7 (MCOPCB7),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ABCC2 causes Dubin-Johnson syndrome,0.0,1.0,0.0,-0.075588435,0.39483184
Defective ABCC6 causes pseudoxanthoma elasticum (PXE),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ABCC8 can cause hypoglycemias and hyperglycemias,0.0,1.0,0.0,-0.075588435,0.39483184
"Defective ABCC9 causes dilated cardiomyopathy 10, familial atrial fibrillation 12 and hypertrichotic osteochondrodysplasia",0.0,1.0,0.0,-0.075588435,0.39483184
Defective ABCD1 causes adrenoleukodystrophy (ALD),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective ABCD4 causes methylmalonic aciduria and homocystinuria, cblj type (MAHCJ)",0.0,2.0,0.0,-0.075588435,0.3491488
Defective ABCG5 causes sitosterolemia,0.0,1.0,0.0,-0.075588435,0.39483184
Defective ABCG8 causes gallbladder disease 4 and sitosterolemia,0.0,1.0,0.0,-0.075588435,0.39483184
Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD),2.1326163e-12,2.0,2.1326163e-12,-0.075588435,0.3491488
Defective ACY1 causes encephalopathy,0.0,1.0,0.0,-0.075588435,0.39483184
Defective AHCY causes Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency (HMAHCHD),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ALG1 causes ALG1-CDG (CDG-1k),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ALG11 causes ALG11-CDG (CDG-1p),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ALG12 causes ALG12-CDG (CDG-1g),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ALG2 causes ALG2-CDG (CDG-1i),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ALG3 causes ALG3-CDG (CDG-1d),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ALG6 causes ALG6-CDG (CDG-1c),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ALG8 causes ALG8-CDG (CDG-1h),0.0,1.0,0.0,-0.075588435,0.39483184
Defective ALG9 causes ALG9-CDG (CDG-1l),0.0,1.0,0.0,-0.075588435,0.39483184
Defective AMN causes hereditary megaloblastic anemia 1,0.0,1.0,0.0,-0.075588435,0.39483184
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),4.035189e-09,2.0,4.035189e-09,-0.07558608,0.34915057
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),4.035189e-09,2.0,4.035189e-09,-0.07558608,0.34915057
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),5.9986996e-07,2.0,5.9986996e-07,-0.07523812,0.34941065
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),5.9986996e-07,2.0,5.9986996e-07,-0.07523812,0.34941065
Defective B3GALT6 causes EDSP2 and SEMDJL1,8.825632e-09,4.0,8.825632e-09,-0.07558329,0.25778663
Defective B3GALTL causes Peters-plus syndrome (PpS),6.65184e-12,2.0,6.65184e-12,-0.075588435,0.3491488
Defective B3GAT3 causes JDSSDHD,6.7842937e-10,4.0,6.7842937e-10,-0.07558803,0.2577831
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.075588435,0.39483184
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.075588435,0.39483184
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.075588435,0.39483184
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective B4GALT7 causes EDS, progeroid type",7.670963e-10,4.0,7.670963e-10,-0.07558798,0.25778311
Defective BTD causes biotidinase deficiency,0.0,1.0,0.0,-0.075588435,0.39483184
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS),9.2014e-10,3.0,9.2014e-10,-0.0755879,0.3034662
Defective CD320 causes methylmalonic aciduria,5.3854103e-09,3.0,5.3854103e-09,-0.07558529,0.30346814
Defective CFTR causes cystic fibrosis,2.0694405e-07,38.0,2.0694405e-07,-0.07546759,-1.2953489
"Defective CHST14 causes EDS, musculocontractural type",5.322695e-11,2.0,5.322695e-11,-0.0755884,0.34914884
Defective CHST3 causes SEDCJD,9.2355915e-11,2.0,9.2355915e-11,-0.07558838,0.34914884
Defective CHST6 causes MCDC1,0.0,1.0,0.0,-0.075588435,0.39483184
Defective CHSY1 causes TPBS,4.505679e-10,2.0,4.505679e-10,-0.07558817,0.34914902
Defective CP causes aceruloplasminemia (ACERULOP),0.0,1.0,0.0,-0.075588435,0.39483184
Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4),3.947271e-08,2.0,3.947271e-08,-0.075565375,0.34916604
Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5),5.3340604e-10,2.0,5.3340604e-10,-0.075588115,0.34914905
Defective CUBN causes hereditary megaloblastic anemia 1,0.0,1.0,0.0,-0.075588435,0.39483184
"Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)",8.680502e-11,3.0,8.680502e-11,-0.07558838,0.30346584
Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4),0.0,1.0,0.0,-0.075588435,0.39483184
Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency),0.0,1.0,0.0,-0.075588435,0.39483184
Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5),0.0,1.0,0.0,-0.075588435,0.39483184
Defective CYP19A1 causes Aromatase excess syndrome (AEXS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective CYP1B1 causes Glaucoma,0.0,1.0,0.0,-0.075588435,0.39483184
Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)",0.0,1.0,0.0,-0.075588435,0.39483184
Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA),0.0,1.0,0.0,-0.075588435,0.39483184
Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4),0.0,1.0,0.0,-0.075588435,0.39483184
Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX),0.0,1.0,0.0,-0.075588435,0.39483184
Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A),0.0,1.0,0.0,-0.075588435,0.39483184
Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)",0.0,1.0,0.0,-0.075588435,0.39483184
"Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)",0.0,1.0,0.0,-0.075588435,0.39483184
"Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)",0.0,1.0,0.0,-0.075588435,0.39483184
Defective DHDDS causes retinitis pigmentosa 59,0.0,1.0,0.0,-0.075588435,0.39483184
Defective DOLK causes DOLK-CDG (CDG-1m),0.0,1.0,0.0,-0.075588435,0.39483184
Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2,0.0,1.0,0.0,-0.075588435,0.39483184
Defective DPM1 causes DPM1-CDG (CDG-1e),0.0,1.0,0.0,-0.075588435,0.39483184
Defective DPM2 causes DPM2-CDG (CDG-1u),0.0,1.0,0.0,-0.075588435,0.39483184
Defective DPM3 causes DPM3-CDG (CDG-1o),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective EXT1 causes exostoses 1, TRPS2 and CHDS",1.7011742e-10,3.0,1.7011742e-10,-0.07558833,0.30346587
Defective EXT2 causes exostoses 2,4.6584603e-10,3.0,4.6584603e-10,-0.07558816,0.30346602
Defective FMO3 causes Trimethylaminuria (TMAU),0.0,1.0,0.0,-0.075588435,0.39483184
Defective GALE can cause Epimerase-deficiency galactosemia (EDG),0.0,1.0,0.0,-0.075588435,0.39483184
Defective GALK1 can cause Galactosemia II (GALCT2),0.0,1.0,0.0,-0.075588435,0.39483184
Defective GALNT12 causes colorectal cancer 1 (CRCS1),8.079082e-11,3.0,8.079082e-11,-0.07558838,0.30346584
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC),5.3859183e-12,3.0,5.3859183e-12,-0.075588435,0.30346578
Defective GALT can cause Galactosemia,0.0,1.0,0.0,-0.075588435,0.39483184
Defective GCK causes maturity-onset diabetes of the young 2 (MODY2),0.0,1.0,0.0,-0.075588435,0.39483184
Defective GCLC causes Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency (HAGGSD),0.0,1.0,0.0,-0.075588435,0.39483184
Defective GFPT1 causes CMSTA1,0.0,1.0,0.0,-0.075588435,0.39483184
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.075588435,0.39483184
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.075588435,0.39483184
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.075588435,0.39483184
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.075588435,0.39483184
Defective GIF causes intrinsic factor deficiency,0.0,1.0,0.0,-0.075588435,0.39483184
"Defective GNE causes sialuria, Nonaka myopathy and inclusion body myopathy 2",0.0,1.0,0.0,-0.075588435,0.39483184
Defective GSS causes Glutathione synthetase deficiency (GSS deficiency),0.0,1.0,0.0,-0.075588435,0.39483184
Defective HEXA causes GM2G1,0.0,1.0,0.0,-0.075588435,0.39483184
Defective HEXB causes GM2G2,0.0,1.0,0.0,-0.075588435,0.39483184
Defective HK1 causes hexokinase deficiency (HK deficiency),0.0,1.0,0.0,-0.075588435,0.39483184
Defective HLCS causes multiple carboxylase deficiency,4.3710816e-07,6.0,4.3710816e-07,-0.07533317,0.16660759
Defective LARGE causes MDDGA6 and MDDGB6,0.0,1.0,0.0,-0.075588435,0.39483184
Defective LFNG causes SCDO3,2.1960699e-10,4.0,2.1960699e-10,-0.07558831,0.25778288
Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF,0.0,1.0,0.0,-0.075588435,0.39483184
Defective MAN1B1 causes MRT15,0.0,1.0,0.0,-0.075588435,0.39483184
Defective MAOA causes Brunner syndrome (BRUNS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective MAT1A causes Methionine adenosyltransferase deficiency (MATD),0.0,1.0,0.0,-0.075588435,0.39483184
Defective MGAT2 causes MGAT2-CDG (CDG-2a),0.0,1.0,0.0,-0.075588435,0.39483184
Defective MMAA causes methylmalonic aciduria type cblA,8.9748826e-11,2.0,8.9748826e-11,-0.07558838,0.34914884
Defective MMAB causes methylmalonic aciduria type cblB,0.0,1.0,0.0,-0.075588435,0.39483184
Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC,6.9596916e-13,2.0,6.9596916e-13,-0.075588435,0.3491488
Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD,1.98435e-10,3.0,1.98435e-10,-0.075588316,0.30346587
Defective MOGS causes MOGS-CDG (CDG-2b),0.0,1.0,0.0,-0.075588435,0.39483184
Defective MPDU1 causes MPDU1-CDG (CDG-1f),0.0,1.0,0.0,-0.075588435,0.39483184
Defective MPI causes MPI-CDG (CDG-1b),0.0,1.0,0.0,-0.075588435,0.39483184
Defective MTR causes methylmalonic aciduria and homocystinuria type cblG,4.378766e-09,3.0,4.378766e-09,-0.07558587,0.30346772
Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE,5.4216485e-11,3.0,5.4216485e-11,-0.0755884,0.30346584
Defective MUT causes methylmalonic aciduria mut type,0.0,1.0,0.0,-0.075588435,0.39483184
Defective Mismatch Repair Associated With MLH1,6.825149e-12,3.0,6.825149e-12,-0.075588435,0.30346578
Defective Mismatch Repair Associated With MSH2,1.8135729e-10,3.0,1.8135729e-10,-0.07558833,0.30346587
Defective Mismatch Repair Associated With MSH3,3.0441882e-10,2.0,3.0441882e-10,-0.075588256,0.34914896
Defective Mismatch Repair Associated With MSH6,2.556844e-12,2.0,2.556844e-12,-0.075588435,0.3491488
Defective Mismatch Repair Associated With PMS2,7.091822e-11,3.0,7.091822e-11,-0.07558839,0.30346584
Defective NEU1 causes sialidosis,0.0,1.0,0.0,-0.075588435,0.39483184
Defective OPLAH causes 5-oxoprolinase deficiency (OPLAHD),0.0,1.0,0.0,-0.075588435,0.39483184
Defective PAPSS2 causes SEMD-PA,0.0,1.0,0.0,-0.075588435,0.39483184
Defective PGM1 causes PGM1-CDG (CDG1t),0.0,1.0,0.0,-0.075588435,0.39483184
Defective PMM2 causes PMM2-CDG (CDG-1a),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3",1.4776884e-14,2.0,1.4776884e-14,-0.075588435,0.3491488
"Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1",2.0828904e-15,2.0,2.0828904e-15,-0.075588435,0.3491488
"Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2",3.8128155e-12,2.0,3.8128155e-12,-0.075588435,0.3491488
Defective RFT1 causes RFT1-CDG (CDG-1n),0.0,1.0,0.0,-0.075588435,0.39483184
Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SFTPA2 causes idiopathic pulmonary fibrosis (IPF),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1)",0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC12A1 causes Bartter syndrome 1 (BS1),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC12A3 causes Gitelman syndrome (GS),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN)",0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC17A5 causes Salla disease (SD) and ISSD,0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC1A3 causes episodic ataxia 6 (EA6),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC22A12 causes renal hypouricemia 1 (RHUC1),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC26A2 causes chondrodysplasias,0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC26A4 causes Pendred syndrome (PDS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC2A10 causes arterial tortuosity syndrome (ATS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC2A9 causes hypouricemia renal 2 (RHUC2),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC33A1 causes spastic paraplegia 42 (SPG42),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC35A2 causes congenital disorder of glycosylation 2M (CDG2M),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS)",0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC35D1 causes Schneckenbecken dysplasia (SCHBCKD),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ)",0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC3A1 causes cystinuria (CSNU),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0,1.0,0.0,-0.075588435,0.39483184
"Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)",0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC5A2 causes renal glucosuria (GLYS1),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A2 causes orthostatic intolerance (OI),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC6A5 causes hyperekplexia 3 (HKPX3),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC7A9 causes cystinuria (CSNU),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective SLC9A6 causes  X-linked, syndromic mental retardation,, Christianson type (MRXSCH)",0.0,1.0,0.0,-0.075588435,0.39483184
Defective SLC9A9 causes autism 16 (AUTS16),0.0,1.0,0.0,-0.075588435,0.39483184
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",3.6622524e-08,2.0,3.6622524e-08,-0.075567044,0.3491648
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",3.6622524e-08,1.0,3.6622524e-08,-0.075567044,0.3948478
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,2.0,0.0,-0.075588435,0.3491488
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,1.0,0.0,-0.075588435,0.39483184
"Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)",3.3114939e-10,2.0,3.3114939e-10,-0.075588234,0.34914896
"Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)",0.0,1.0,0.0,-0.075588435,0.39483184
Defective SRD5A3 causes SRD5A3-CDG (CDG-1q) and KHRZ,0.0,1.0,0.0,-0.075588435,0.39483184
Defective ST3GAL3 causes MCT12 and EIEE15,0.0,1.0,0.0,-0.075588435,0.39483184
Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD),0.0,1.0,0.0,-0.075588435,0.39483184
Defective TCN2 causes hereditary megaloblastic anemia,4.2526025e-16,2.0,4.2526025e-16,-0.075588435,0.3491488
Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency),0.0,1.0,0.0,-0.075588435,0.39483184
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC),0.0,1.0,0.0,-0.075588435,0.39483184
Defective UGT1A1 causes hyperbilirubinemia,0.0,1.0,0.0,-0.075588435,0.39483184
Defective UGT1A4 causes hyperbilirubinemia,0.0,1.0,0.0,-0.075588435,0.39483184
Defective pro-SFTPB causes pulmonary surfactant metabolism dysfunction 1 (SMDP1) and respiratory distress syndrome (RDS),1.5138847e-08,4.0,1.5138847e-08,-0.07557959,0.25778937
Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS),1.573213e-10,2.0,1.573213e-10,-0.07558834,0.3491489
Degradation of AXIN,8.213009e-07,34.0,8.213009e-07,-0.07510882,-1.1123488
Degradation of DVL,5.1531955e-05,35.0,5.1531955e-05,-0.0454954,-1.1358966
Degradation of GABA,2.8032996e-08,2.0,2.8032996e-08,-0.075572066,0.34916106
Degradation of GLI1 by the proteasome,1.12428026e-07,36.0,1.12428026e-07,-0.07552278,-1.2040242
Degradation of GLI2 by the proteasome,6.256e-07,35.0,6.256e-07,-0.0752231,-1.1581172
Deletions in the AMER1 gene destabilize the destruction complex,1.3207108e-07,2.0,1.3207108e-07,-0.07551131,0.34920645
Deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling,6.1104e-10,2.0,6.1104e-10,-0.07558808,0.34914908
Deposition of new CENPA-containing nucleosomes at the centromere,7.744017e-08,20.0,7.744017e-08,-0.07554321,-0.47311145
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,2.3894356e-07,14.0,2.3894356e-07,-0.0754489,-0.19894294
Dermatan sulfate biosynthesis,0.00012532528,4.0,0.00012532528,-0.0024024213,0.31248713
Detoxification of Reactive Oxygen Species,2.4277648e-07,12.0,2.4277648e-07,-0.075446665,-0.10757525
Digestion of dietary carbohydrate,1.6223089e-06,5.0,1.6223089e-06,-0.07464106,0.21280792
Digestion of dietary lipid,3.2800868e-10,3.0,3.2800868e-10,-0.075588234,0.30346593
Dimerization of procaspase-8,0.00010982608,8.0,0.00010982608,-0.01145347,0.12298974
Disassembly of the destruction complex and recruitment of AXIN to the membrane,5.8641695e-07,19.0,5.8641695e-07,-0.075245984,-0.42720625
Disinhibition of SNARE formation,1.4100365e-07,3.0,1.4100365e-07,-0.07550609,0.30352733
Displacement of DNA glycosylase by APEX1,1.2550682e-06,8.0,1.2550682e-06,-0.07485551,0.075598635
Dissolution of Fibrin Clot,7.4186936e-08,3.0,7.4186936e-08,-0.07554511,0.30349818
Dopamine Neurotransmitter Release Cycle,4.774524e-07,7.0,4.774524e-07,-0.07530962,0.1209422
Downregulation of ERBB2:ERBB3 signaling,6.896625e-07,10.0,6.896625e-07,-0.075185694,-0.016014183
Downregulation of ERBB4 signaling,2.6240193e-07,7.0,2.6240193e-07,-0.0754352,0.12084833
Downregulation of SMAD2/3:SMAD4 transcriptional activity,0.00048187247,18.0,0.00048187247,0.20580989,-0.17144254
Downregulation of TGF-beta receptor signaling,1.0104324e-06,19.0,1.0104324e-06,-0.07499838,-0.42702118
Downstream TCR signaling,2.4975598e-05,56.0,2.4975598e-05,-0.061003473,-2.1068316
Downstream signal transduction,7.836857e-09,24.0,7.836857e-09,-0.07558385,-0.65587384
Downstream signaling of activated FGFR1,2.2060897e-08,14.0,2.2060897e-08,-0.07557555,-0.19903761
Downstream signaling of activated FGFR2,9.987465e-09,14.0,9.987465e-09,-0.0755826,-0.19904286
Downstream signaling of activated FGFR3,6.246259e-09,14.0,6.246259e-09,-0.075584784,-0.19904451
Downstream signaling of activated FGFR4,1.0782163e-08,15.0,1.0782163e-08,-0.07558214,-0.24472554
Dual Incision in GG-NER,2.414906e-05,30.0,2.414906e-05,-0.06148614,-0.91943425
Dual incision in TC-NER,2.6313721e-06,48.0,2.6313721e-06,-0.07405179,-1.7511207
E2F mediated regulation of DNA replication,2.8713414e-06,15.0,2.8713414e-06,-0.07391166,-0.2434769
E3 ubiquitin ligases ubiquitinate target proteins,0.002125645,31.0,0.002125645,1.1657213,-0.047816947
ECM proteoglycans,0.00018856024,13.0,0.00018856024,0.0345248,-0.07105792
EGFR downregulation,1.1513199e-08,17.0,1.1513199e-08,-0.07558171,-0.3360912
EGFR interacts with phospholipase C-gamma,1.0939948e-09,3.0,1.0939948e-09,-0.075587794,0.3034663
EPH-ephrin mediated repulsion of cells,1.7683573e-05,28.0,1.7683573e-05,-0.06526178,-0.8308904
EPHA-mediated growth cone collapse,2.0661364e-06,10.0,2.0661364e-06,-0.07438187,-0.015413347
EPHB-mediated forward signaling,1.8101078e-05,26.0,1.8101078e-05,-0.065017976,-0.7393421
ER-Phagosome pathway,2.3580239e-07,45.0,2.3580239e-07,-0.07545073,-1.6151174
ERBB2 Activates PTK6 Signaling,6.608082e-06,6.0,6.608082e-06,-0.07172952,0.16930121
ERBB2 Regulates Cell Motility,1.3706068e-06,7.0,1.3706068e-06,-0.07478804,0.121332064
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0001600162,17.0,0.0001600162,0.017855981,-0.26624936
Early Phase of HIV Life Cycle,1.7056817e-09,7.0,1.7056817e-09,-0.07558744,0.120734535
Eicosanoid ligand-binding receptors,0.0,1.0,0.0,-0.075588435,0.39483184
Eicosanoids,1.01853075e-05,2.0,1.01853075e-05,-0.06964053,0.3535947
Electric Transmission Across Gap Junctions,4.431283e-06,3.0,4.431283e-06,-0.07300071,0.30540004
Electron transport from NADPH to Ferredoxin,6.0488884e-07,3.0,6.0488884e-07,-0.075235195,0.30372983
Elevation of cytosolic Ca2+ levels,1.0832585e-08,5.0,1.0832585e-08,-0.07558211,0.21210451
Endogenous sterols,2.1445172e-07,4.0,2.1445172e-07,-0.0754632,0.2578764
Endosomal Sorting Complex Required For Transport (ESCRT),3.1500007e-05,23.0,3.1500007e-05,-0.05719342,-0.59644455
Endosomal/Vacuolar pathway,3.7902828e-09,7.0,3.7902828e-09,-0.07558622,0.12073545
Energy dependent regulation of mTOR by LKB1-AMPK,1.495215e-05,23.0,1.495215e-05,-0.066856846,-0.6036677
Entry of Influenza Virion into Host Cell via Endocytosis,0.0,1.0,0.0,-0.075588435,0.39483184
Enzymatic degradation of Dopamine by monoamine oxidase,2.4519902e-09,2.0,2.4519902e-09,-0.075587004,0.34914988
Enzymatic degradation of dopamine by COMT,1.25342625e-08,2.0,1.25342625e-08,-0.07558112,0.3491543
Ephrin signaling,1.868401e-05,12.0,1.868401e-05,-0.06467756,-0.09952567
Erythrocytes take up carbon dioxide and release oxygen,5.2823438e-08,7.0,5.2823438e-08,-0.07555758,0.120756865
Erythrocytes take up oxygen and release carbon dioxide,3.7620225e-07,4.0,3.7620225e-07,-0.07536875,0.257947
Essential fructosuria,0.0,1.0,0.0,-0.075588435,0.39483184
Essential pentosuria,0.0,1.0,0.0,-0.075588435,0.39483184
Establishment of Sister Chromatid Cohesion,1.0469225e-05,7.0,1.0469225e-05,-0.069474734,0.12530361
Estrogen biosynthesis,0.0,1.0,0.0,-0.075588435,0.39483184
Estrogen-dependent gene expression,5.4878196e-06,72.0,5.4878196e-06,-0.07238372,-2.846266
Ethanol oxidation,9.87411e-07,5.0,9.87411e-07,-0.07501182,0.2125308
Eukaryotic Translation Termination,1.239502e-06,33.0,1.239502e-06,-0.0748646,-1.0664833
Export of Viral Ribonucleoproteins from Nucleus,2.3368054e-11,3.0,2.3368054e-11,-0.07558841,0.3034658
Extrinsic Pathway of Fibrin Clot Formation,2.0047786e-08,2.0,2.0047786e-08,-0.07557672,0.34915757
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis,1.9720419e-07,34.0,1.9720419e-07,-0.07547327,-1.1126212
FCERI mediated Ca+2 mobilization,2.8797955e-05,18.0,2.8797955e-05,-0.058771335,-0.369209
FCERI mediated MAPK activation,0.00015016843,21.0,0.00015016843,0.012105192,-0.4532799
FCERI mediated NF-kB activation,0.0017132338,53.0,0.0017132338,0.924886,-1.2328598
FCGR activation,5.681191e-06,7.0,5.681191e-06,-0.0722708,0.12321363
FGFR1 ligand binding and activation,4.709019e-10,3.0,4.709019e-10,-0.07558816,0.30346602
FGFR1 mutant receptor activation,8.400855e-10,17.0,8.400855e-10,-0.07558794,-0.33609587
FGFR2 alternative splicing,9.901748e-08,18.0,9.901748e-08,-0.07553061,-0.38173598
FGFR2 ligand binding and activation,1.3369326e-09,3.0,1.3369326e-09,-0.07558765,0.30346638
FGFR2 mutant receptor activation,1.1898891e-13,14.0,1.1898891e-13,-0.075588435,-0.19904724
FGFR3 ligand binding and activation,1.6494369e-09,3.0,1.6494369e-09,-0.075587474,0.3034665
FGFR4 ligand binding and activation,7.9657225e-10,4.0,7.9657225e-10,-0.075587966,0.25778314
FGFR4 mutant receptor activation,0.0,1.0,0.0,-0.075588435,0.39483184
FGFRL1 modulation of FGFR1 signaling,6.0908225e-09,3.0,6.0908225e-09,-0.07558487,0.30346847
FMO oxidises nucleophiles,7.3036494e-11,2.0,7.3036494e-11,-0.07558839,0.34914884
Fanconi Anemia Pathway,0.002411404,18.0,0.002411404,1.3325953,0.6707955
FasL/ CD95L signaling,1.6407386e-08,4.0,1.6407386e-08,-0.075578846,0.25778994
Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion,9.046576e-08,6.0,9.046576e-08,-0.0755356,0.16645627
Fatty acids,1.3164742e-05,2.0,1.3164742e-05,-0.06790064,0.3548952
Fibronectin matrix formation,0.0,1.0,0.0,-0.075588435,0.39483184
Folding of actin by CCT/TriC,2.5000998e-07,7.0,2.5000998e-07,-0.07544243,0.120842926
Formation of ATP by chemiosmotic coupling,0.0,1.0,0.0,-0.075588435,0.39483184
Formation of Incision Complex in GG-NER,8.5441724e-07,33.0,8.5441724e-07,-0.075089484,-1.0666512
Formation of RNA Pol II elongation complex ,7.764565e-07,42.0,7.764565e-07,-0.07513501,-1.4778324
Formation of Senescence-Associated Heterochromatin Foci (SAHF),0.00020300246,7.0,0.00020300246,0.0429586,0.2093441
Formation of TC-NER Pre-Incision Complex,0.0015112936,43.0,0.0015112936,0.8069593,-0.8641766
Formation of a pool of free 40S subunits,3.9181945e-05,41.0,3.9181945e-05,-0.05270741,-1.4153854
Formation of editosomes by ADAR proteins,1.6341356e-07,2.0,1.6341356e-07,-0.075493,0.34922016
Formation of selenosugars for excretion,0.0,1.0,0.0,-0.075588435,0.39483184
Formation of the Early Elongation Complex,4.648535e-07,26.0,4.648535e-07,-0.07531698,-0.74704033
Formation of the Editosome,2.247713e-07,3.0,2.247713e-07,-0.07545718,0.30356392
"Formation of the active cofactor, UDP-glucuronate",0.0,1.0,0.0,-0.075588435,0.39483184
Formation of the cornified envelope,0.0008010243,21.0,0.0008010243,0.3921845,-0.16918214
"Formation of the ternary complex, and subsequently, the 43S complex",2.7986137e-06,26.0,2.7986137e-06,-0.073954135,-0.7460216
Formation of tubulin folding intermediates by CCT/TriC,5.2567064e-08,11.0,5.2567064e-08,-0.07555774,-0.06197527
Formation of xylulose-5-phosphate,3.0191e-06,3.0,3.0191e-06,-0.073825374,0.30478364
Free fatty acid receptors,1.4234499e-12,2.0,1.4234499e-12,-0.075588435,0.3491488
Fructose biosynthesis,7.8925694e-07,3.0,7.8925694e-07,-0.075127535,0.3038103
Fructose catabolism,0.0002887757,5.0,0.0002887757,0.093047455,0.33815
Fusion and Uncoating of the Influenza Virion,0.0,1.0,0.0,-0.075588435,0.39483184
G alpha (12/13) signalling events,2.274478e-05,46.0,2.274478e-05,-0.0623062,-1.6509753
G alpha (z) signalling events,1.2405097e-06,17.0,1.2405097e-06,-0.074864015,-0.33555475
G beta:gamma signalling through PI3Kgamma,5.7486665e-07,14.0,5.7486665e-07,-0.07525273,-0.19879629
G beta:gamma signalling through PLC beta,1.3434155e-07,12.0,1.3434155e-07,-0.07550998,-0.107622586
G1/S-Specific Transcription,5.9901167e-06,8.0,5.9901167e-06,-0.07209039,0.07766548
G2 Phase,4.781136e-07,3.0,4.781136e-07,-0.075309224,0.3036745
G2/M DNA replication checkpoint,3.1800684e-07,2.0,3.1800684e-07,-0.07540273,0.34928763
GAB1 signalosome,6.6742967e-09,8.0,6.6742967e-09,-0.07558453,0.075053714
GABA A (rho) receptor activation,0.0,1.0,0.0,-0.075588435,0.39483184
GABA A receptor activation,4.3756474e-09,3.0,4.3756474e-09,-0.07558587,0.30346772
GABA B receptor activation,1.8332148e-05,16.0,1.8332148e-05,-0.06488304,-0.28241128
GABA synthesis,0.0,1.0,0.0,-0.075588435,0.39483184
GLI proteins bind promoters of Hh responsive genes to promote transcription,9.031846e-06,2.0,9.031846e-06,-0.07031412,0.3530912
GLI3 is processed to GLI3R by the proteasome,1.01757124e-07,36.0,1.01757124e-07,-0.07552901,-1.2040288
GP1b-IX-V activation signalling,1.1440949e-05,6.0,1.1440949e-05,-0.06890728,0.17141075
GPVI-mediated activation cascade,1.7605289e-05,22.0,1.7605289e-05,-0.0653075,-0.55682653
GRB2 events in EGFR signaling,2.7084293e-11,5.0,2.7084293e-11,-0.07558841,0.2120998
GRB2 events in ERBB2 signaling,3.8545663e-06,8.0,3.8545663e-06,-0.07333749,0.07673331
GRB2:SOS provides linkage to MAPK signaling for Integrins ,9.811167e-06,7.0,9.811167e-06,-0.06985902,0.12501636
GRB7 events in ERBB2 signaling,1.9167639e-07,4.0,1.9167639e-07,-0.0754765,0.25786644
GTP hydrolysis and joining of the 60S ribosomal subunit,3.7152046e-07,49.0,3.7152046e-07,-0.075371474,-1.7977902
Galactose catabolism,2.1413756e-05,5.0,2.1413756e-05,-0.06308348,0.22144686
Gamma-carboxylation of protein precursors,0.0,1.0,0.0,-0.075588435,0.39483184
Gap junction assembly,2.7677768e-08,3.0,2.7677768e-08,-0.07557227,0.30347788
Gap junction degradation,4.0188715e-07,6.0,4.0188715e-07,-0.07535375,0.16659221
Gap-filling DNA repair synthesis and ligation in GG-NER,2.7733856e-06,18.0,2.7733856e-06,-0.07396886,-0.38056862
Gap-filling DNA repair synthesis and ligation in TC-NER,0.0001737588,48.0,0.0001737588,0.025881225,-1.6764238
Gastrin-CREB signalling pathway via PKC and MAPK,6.120686e-07,11.0,6.120686e-07,-0.075231,-0.06173105
Generation of second messenger molecules,1.1882014e-05,13.0,1.1882014e-05,-0.06864971,-0.14817774
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,2.0438108e-06,16.0,2.0438108e-06,-0.07439491,-0.28952113
Glucagon-type ligand receptors,2.421087e-07,11.0,2.421087e-07,-0.075447045,-0.061892536
Glucocorticoid biosynthesis,0.0,1.0,0.0,-0.075588435,0.39483184
Gluconeogenesis,3.320277e-05,20.0,3.320277e-05,-0.056199063,-0.4586523
Glutamate Neurotransmitter Release Cycle,6.690814e-06,8.0,6.690814e-06,-0.07168121,0.077971324
Glutathione synthesis and recycling,6.1403387e-07,6.0,6.1403387e-07,-0.07522985,0.16668482
Glycerophospholipid catabolism,9.324508e-07,4.0,9.324508e-07,-0.07504391,0.2581898
Glycine degradation,7.62951e-07,3.0,7.62951e-07,-0.07514289,0.30379882
Glycogen breakdown (glycogenolysis),9.329865e-06,13.0,9.329865e-06,-0.070140086,-0.14929175
Glycogen storage disease type 0 (liver GYS2),0.0,1.0,0.0,-0.075588435,0.39483184
Glycogen storage disease type 0 (muscle GYS1),2.9633922e-09,3.0,2.9633922e-09,-0.0755867,0.3034671
Glycogen storage disease type II (GAA),1.204707e-09,2.0,1.204707e-09,-0.07558773,0.34914935
Glycogen storage disease type IV (GBE1),0.0,1.0,0.0,-0.075588435,0.39483184
Glycogen storage disease type Ia (G6PC),0.0,1.0,0.0,-0.075588435,0.39483184
Glycogen storage disease type Ib (SLC37A4),0.0,1.0,0.0,-0.075588435,0.39483184
Glycogen storage disease type XV (GYG1),2.9721097e-09,3.0,2.9721097e-09,-0.0755867,0.3034671
Glycogen synthesis,7.687894e-06,10.0,7.687894e-06,-0.071098946,-0.012959463
Glycoprotein hormones,0.0,1.0,0.0,-0.075588435,0.39483184
Glycosphingolipid metabolism,1.9632216e-06,20.0,1.9632216e-06,-0.07444197,-0.4722883
Golgi Associated Vesicle Biogenesis,7.7468885e-06,43.0,7.7468885e-06,-0.071064495,-1.5204728
Golgi Cisternae Pericentriolar Stack Reorganization,2.4640522e-05,10.0,2.4640522e-05,-0.061199144,-0.0055596596
Growth hormone receptor signaling,2.2663187e-05,13.0,2.2663187e-05,-0.062353846,-0.14347176
HATs acetylate histones,3.747613e-07,61.0,3.747613e-07,-0.07536959,-2.345985
HCN channels,2.3106404e-07,3.0,2.3106404e-07,-0.0754535,0.30356666
HDACs deacetylate histones,0.00042575438,26.0,0.00042575438,0.17303868,-0.56140196
HDL assembly,2.2252136e-06,4.0,2.2252136e-06,-0.07428897,0.25875407
HDL clearance,1.202618e-05,3.0,1.202618e-05,-0.06856552,0.3087152
HDL remodeling,0.00019513123,4.0,0.00019513123,0.03836205,0.34295732
HDMs demethylate histones,9.3250785e-09,19.0,9.3250785e-09,-0.07558299,-0.42745817
HDR through Homologous Recombination (HRR),0.0028279088,42.0,0.0028279088,1.5758212,-0.24379274
HDR through MMEJ (alt-NHEJ),4.8121667e-05,8.0,4.8121667e-05,-0.047486898,0.09605585
HDR through Single Strand Annealing (SSA),0.0006311837,24.0,0.0006311837,0.29300293,-0.38036636
HHAT G278V abrogates palmitoylation of Hh-Np,0.0,1.0,0.0,-0.075588435,0.39483184
HS-GAG biosynthesis,0.0035190715,10.0,0.0035190715,1.9794383,1.519755
HS-GAG degradation,0.0001696545,6.0,0.0001696545,0.023484437,0.24047074
HSF1 activation,5.9932125e-07,11.0,5.9932125e-07,-0.07523845,-0.061736617
HSP90 chaperone cycle for steroid hormone receptors (SHR),2.7662168e-08,14.0,2.7662168e-08,-0.075572275,-0.19903517
Heme biosynthesis,7.655719e-06,7.0,7.655719e-06,-0.07111774,0.12407552
Heme degradation,7.607113e-07,3.0,7.607113e-07,-0.0751442,0.30379784
Hereditary fructose intolerance,0.0,1.0,0.0,-0.075588435,0.39483184
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD,2.431696e-07,35.0,2.431696e-07,-0.075446434,-1.1582841
Histidine catabolism,0.00011008497,5.0,0.00011008497,-0.011302285,0.26015174
Hormone ligand-binding receptors,1.616882e-10,2.0,1.616882e-10,-0.07558834,0.3491489
HuR (ELAVL1) binds and stabilizes mRNA,2.4608323e-07,8.0,2.4608323e-07,-0.07544473,0.07515821
Hyaluronan biosynthesis and export,0.0,1.0,0.0,-0.075588435,0.39483184
Hyaluronan uptake and degradation,0.00018321148,8.0,0.00018321148,0.031401288,0.15502237
Hydrolysis of LPC,5.0906685e-08,4.0,5.0906685e-08,-0.07555871,0.25780502
Hydrolysis of LPE,5.9349436e-08,2.0,5.9349436e-08,-0.075553775,0.3491747
Hydroxycarboxylic acid-binding receptors,0.0,1.0,0.0,-0.075588435,0.39483184
Hypusine synthesis from eIF5A-lysine,2.9955411e-09,5.0,2.9955411e-09,-0.075586684,0.21210109
IKBKB deficiency causes SCID,5.7782e-14,2.0,5.7782e-14,-0.075588435,0.3491488
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR),7.260849e-08,3.0,7.260849e-08,-0.075546026,0.3034975
IL-6-type cytokine receptor ligand interactions,1.886165e-06,6.0,1.886165e-06,-0.07448697,0.1672401
IP3 and IP4 transport between cytosol and nucleus,0.0,1.0,0.0,-0.075588435,0.39483184
IP6 and IP7 transport between cytosol and nucleus,0.0,1.0,0.0,-0.075588435,0.39483184
IPs transport between ER lumen and cytosol,0.0,1.0,0.0,-0.075588435,0.39483184
IPs transport between ER lumen and nucleus,0.0,1.0,0.0,-0.075588435,0.39483184
IPs transport between cytosol and ER lumen,0.0,1.0,0.0,-0.075588435,0.39483184
IPs transport between nucleus and ER lumen,0.0,1.0,0.0,-0.075588435,0.39483184
IPs transport between nucleus and cytosol,0.0,1.0,0.0,-0.075588435,0.39483184
IRAK4 deficiency (TLR2/4),1.5699104e-06,5.0,1.5699104e-06,-0.074671656,0.21278505
IRAK4 deficiency (TLR5),1.1975807e-08,4.0,1.1975807e-08,-0.07558144,0.257788
IRF3 mediated activation of type 1 IFN,9.755767e-06,3.0,9.755767e-06,-0.06989137,0.30772418
IRF3-mediated induction of type I IFN,1.5345654e-07,3.0,1.5345654e-07,-0.07549882,0.30353278
IRS activation,1.5115296e-08,3.0,1.5115296e-08,-0.075579606,0.3034724
IRS-mediated signalling,7.095638e-07,22.0,7.095638e-07,-0.07517407,-0.5642015
ISG15 antiviral mechanism,0.0017429158,55.0,0.0017429158,0.9422194,-1.3112699
IkBA variant leads to EDA-ID,1.11989316e-07,7.0,1.11989316e-07,-0.075523034,0.12078268
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,5.10631e-06,27.0,5.10631e-06,-0.07260651,-0.79069734
Import of palmitoyl-CoA into the mitochondrial matrix,1.1775275e-06,8.0,1.1775275e-06,-0.07490079,0.07556479
Inactivation of APC/C via direct inhibition of the APC/C complex,3.4227683e-06,14.0,3.4227683e-06,-0.073589645,-0.1975532
Inactivation of CDC42 and RAC1,1.1391476e-05,5.0,1.1391476e-05,-0.06893617,0.21707217
Influenza Viral RNA Transcription and Replication,1.859055e-08,53.0,1.859055e-08,-0.07557757,-1.9806762
Influenza Virus Induced Apoptosis,0.0,1.0,0.0,-0.075588435,0.39483184
Inhibition of Signaling by Overexpressed EGFR,1.05972726e-13,2.0,1.05972726e-13,-0.075588435,0.3491488
Inhibition of TSC complex formation by PKB,1.7893678e-08,3.0,1.7893678e-08,-0.07557798,0.30347362
InlA-mediated entry of Listeria monocytogenes into host cells,4.0652576e-08,7.0,4.0652576e-08,-0.07556469,0.120751545
InlB-mediated entry of Listeria monocytogenes into host cell,3.7342023e-09,12.0,3.7342023e-09,-0.07558625,-0.10767958
Inositol transporters,4.004793e-08,2.0,4.004793e-08,-0.07556505,0.3491663
Insulin effects increased synthesis of Xylulose-5-Phosphate,2.7458158e-05,2.0,2.7458158e-05,-0.05955374,0.36113426
Insulin processing,1.3939972e-05,17.0,1.3939972e-05,-0.06744793,-0.33001146
Insulin receptor recycling,1.0716121e-08,14.0,1.0716121e-08,-0.07558218,-0.19904254
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA,5.7804747e-05,6.0,5.7804747e-05,-0.041832283,0.19164847
Integrin cell surface interactions,0.0005192342,15.0,0.0005192342,0.22762798,-0.018085154
Interaction With Cumulus Cells,0.0,1.0,0.0,-0.075588435,0.39483184
Interaction With The Zona Pellucida,4.3672205e-07,2.0,4.3672205e-07,-0.0753334,0.34933943
Interaction between L1 and Ankyrins,6.912118e-09,7.0,6.912118e-09,-0.0755844,0.12073682
Interaction between PHLDA1 and AURKA,0.0,1.0,0.0,-0.075588435,0.39483184
Interactions of Rev with host cellular proteins,5.219646e-08,27.0,5.219646e-08,-0.07555795,-0.79290354
Interactions of Tat with host cellular proteins,2.7698956e-11,2.0,2.7698956e-11,-0.07558841,0.3491488
Interactions of Vpr with host cellular proteins,2.3628573e-08,27.0,2.3628573e-08,-0.07557463,-0.79291594
Interconversion of 2-oxoglutarate and 2-hydroxyglutarate,7.4444497e-06,4.0,7.4444497e-06,-0.07124111,0.26103228
Interconversion of nucleotide di- and triphosphates,3.383785e-06,12.0,3.383785e-06,-0.07361241,-0.106204204
Interconversion of polyamines,0.0,1.0,0.0,-0.075588435,0.39483184
Interleukin receptor SHC signaling,2.0805563e-05,13.0,2.0805563e-05,-0.06343864,-0.14428262
Interleukin-1 processing,4.7491375e-07,2.0,4.7491375e-07,-0.075311095,0.3493561
Interleukin-10 signaling,1.1138719e-06,5.0,1.1138719e-06,-0.07493796,0.21258599
Interleukin-12 signaling,1.6240396e-05,23.0,1.6240396e-05,-0.06610455,-0.6031053
Interleukin-15 signaling,9.306255e-07,9.0,9.306255e-07,-0.075044975,0.029774003
Interleukin-18 signaling,1.3026081e-06,2.0,1.3026081e-06,-0.074827746,0.3497174
Interleukin-2 signaling,1.986082e-05,8.0,1.986082e-05,-0.06399034,0.08372001
Interleukin-20 family signaling,1.5303046e-07,10.0,1.5303046e-07,-0.07549907,-0.016248422
Interleukin-21 signaling,2.9835844e-06,6.0,2.9835844e-06,-0.07384612,0.16771911
Interleukin-23 signaling,0.00012155612,4.0,0.00012155612,-0.0046034944,0.3108419
Interleukin-27 signaling,1.1711963e-06,8.0,1.1711963e-06,-0.074904494,0.07556202
Interleukin-33 signaling,3.243134e-06,2.0,3.243134e-06,-0.07369455,0.35056442
Interleukin-35 Signalling,5.784999e-05,8.0,5.784999e-05,-0.041805863,0.10030225
Interleukin-36 pathway,1.287168e-06,3.0,1.287168e-06,-0.07483676,0.30402765
Interleukin-37 signaling,2.5180736e-05,15.0,2.5180736e-05,-0.06088368,-0.23373888
Interleukin-38 signaling,0.0,2.0,0.0,-0.075588435,0.3491488
Interleukin-4 and Interleukin-13 signaling,5.181405e-05,43.0,5.181405e-05,-0.045330662,-1.5012375
Interleukin-6 signaling,3.3852923e-06,8.0,3.3852923e-06,-0.07361153,0.076528475
Interleukin-7 signaling,2.130558e-06,14.0,2.130558e-06,-0.074344255,-0.19811724
Interleukin-9 signaling,6.6973075e-06,6.0,6.6973075e-06,-0.071677424,0.16934015
Intestinal hexose absorption,0.0,1.0,0.0,-0.075588435,0.39483184
Intestinal infectious diseases,0.0,1.0,0.0,-0.075588435,0.39483184
Intestinal lipid absorption,0.0,1.0,0.0,-0.075588435,0.39483184
Intestinal saccharidase deficiencies,0.0,1.0,0.0,-0.075588435,0.39483184
Intra-Golgi traffic,8.5704436e-05,29.0,8.5704436e-05,-0.025539747,-0.8468824
Intracellular oxygen transport,0.0,1.0,0.0,-0.075588435,0.39483184
Intraflagellar transport,4.5374854e-05,25.0,4.5374854e-05,-0.04909095,-0.6817542
Intrinsic Pathway of Fibrin Clot Formation,1.8032262e-05,4.0,1.8032262e-05,-0.065058164,0.26565385
Invadopodia formation,6.0110106e-06,4.0,6.0110106e-06,-0.0720782,0.26040658
Ion homeostasis,0.000117839925,12.0,0.000117839925,-0.0067736353,-0.056244247
Ion influx/efflux at host-pathogen interface,1.4093327e-05,3.0,1.4093327e-05,-0.067358375,0.30961752
Ion transport by P-type ATPases,8.420754e-08,18.0,8.420754e-08,-0.07553925,-0.38174248
Ionotropic activity of kainate receptors,3.2324454e-06,4.0,3.2324454e-06,-0.073700786,0.25919375
Josephin domain DUBs,7.7577646e-08,6.0,7.7577646e-08,-0.07554313,0.16645065
KSRP (KHSRP) binds and destabilizes mRNA,2.6246002e-07,13.0,2.6246002e-07,-0.07543516,-0.15324967
Keratan sulfate biosynthesis,0.0041797413,10.0,0.0041797413,2.3652484,1.8081366
Keratan sulfate degradation,0.00051757076,3.0,0.00051757076,0.22665657,0.5293848
Kinesins,2.6685916e-07,14.0,2.6685916e-07,-0.0754326,-0.19893077
L13a-mediated translational silencing of Ceruloplasmin expression,1.8699335e-05,49.0,1.8699335e-05,-0.06466861,-1.7897902
LDL clearance,3.370612e-05,12.0,3.370612e-05,-0.055905122,-0.09296854
LDL remodeling,0.0,1.0,0.0,-0.075588435,0.39483184
LGI-ADAM interactions,8.6079115e-07,4.0,8.6079115e-07,-0.07508576,0.2581585
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production,3.430489e-05,5.0,3.430489e-05,-0.05555546,0.22707383
Lactose synthesis,1.6623808e-05,3.0,1.6623808e-05,-0.06588065,0.31072205
Laminin interactions,1.7459868e-05,7.0,1.7459868e-05,-0.06539242,0.128355
Late Phase of HIV Life Cycle,9.138839e-09,97.0,9.421484e-11,-0.07558838,-3.990733
Ligand-receptor interactions,0.0,1.0,0.0,-0.075588435,0.39483184
Linoleic acid (LA) metabolism,1.700042e-07,4.0,1.700042e-07,-0.07548915,0.257857
Lipid particle organization,9.848163e-09,3.0,9.848163e-09,-0.07558268,0.30347008
Localization of the PINCH-ILK-PARVIN complex to focal adhesions,0.0,1.0,0.0,-0.075588435,0.39483184
Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling,1.7879889e-07,6.0,1.7879889e-07,-0.07548402,0.16649485
Lysine catabolism,6.8701183e-07,8.0,6.8701183e-07,-0.07518724,0.07535067
Lysosomal oligosaccharide catabolism,3.7234079e-06,5.0,3.7234079e-06,-0.07341408,0.21372508
Lysosome Vesicle Biogenesis,8.56243e-05,22.0,8.56243e-05,-0.025586544,-0.5271363
Lysosphingolipid and LPA receptors,5.747866e-08,6.0,5.747866e-08,-0.07555486,0.16644189
MAP kinase activation,1.5835338e-05,46.0,1.5835338e-05,-0.066341095,-1.6539912
MAP2K and MAPK activation,4.6411174e-07,24.0,4.6411174e-07,-0.075317405,-0.65567464
MAPK1 (ERK2) activation,2.2636504e-08,3.0,2.2636504e-08,-0.07557521,0.30347568
MAPK3 (ERK1) activation,2.2119657e-07,3.0,2.2119657e-07,-0.07545926,0.30356234
MAPK6/MAPK4 signaling,3.0442193e-06,55.0,3.0442193e-06,-0.073810704,-2.0707214
MASTL Facilitates Mitotic Progression,2.489654e-05,8.0,2.489654e-05,-0.06104964,0.0859181
MET Receptor Activation,2.1608208e-11,2.0,2.1608208e-11,-0.07558843,0.3491488
MET activates PI3K/AKT signaling,1.7311104e-08,5.0,1.7311104e-08,-0.07557832,0.21210735
MET activates PTK2 signaling,6.1012937e-09,4.0,6.1012937e-09,-0.07558487,0.25778544
MET activates PTPN11,1.6153333e-06,4.0,1.6153333e-06,-0.074645124,0.25848788
MET activates RAP1 and RAC1,1.6247033e-06,10.0,1.6247033e-06,-0.074639656,-0.015606031
MET activates RAS signaling,1.1634894e-07,8.0,1.1634894e-07,-0.07552049,0.07510158
MET activates STAT3,2.8445246e-10,3.0,2.8445246e-10,-0.07558826,0.30346593
MET interacts with TNS proteins,1.5298506e-08,2.0,1.5298506e-08,-0.0755795,0.3491555
MET receptor recycling,1.8093823e-08,6.0,1.8093823e-08,-0.07557787,0.16642468
MGMT-mediated DNA damage reversal,6.653824e-08,2.0,6.653824e-08,-0.07554958,0.34917787
MHC class II antigen presentation,0.0060408767,56.0,0.0060408767,3.452093,0.51910144
MPS I - Hurler syndrome,0.0,1.0,0.0,-0.075588435,0.39483184
MPS II - Hunter syndrome,0.0,1.0,0.0,-0.075588435,0.39483184
MPS IIIA - Sanfilippo syndrome A,0.0,1.0,0.0,-0.075588435,0.39483184
MPS IIIB - Sanfilippo syndrome B,0.0,1.0,0.0,-0.075588435,0.39483184
MPS IIIC - Sanfilippo syndrome C,0.0,1.0,0.0,-0.075588435,0.39483184
MPS IIID - Sanfilippo syndrome D,0.0,1.0,0.0,-0.075588435,0.39483184
MPS IV - Morquio syndrome A,0.0,1.0,0.0,-0.075588435,0.39483184
MPS IV - Morquio syndrome B,0.0,1.0,0.0,-0.075588435,0.39483184
MPS IX - Natowicz syndrome,0.0,1.0,0.0,-0.075588435,0.39483184
MPS VI - Maroteaux-Lamy syndrome,0.0,1.0,0.0,-0.075588435,0.39483184
MPS VII - Sly syndrome,0.0,1.0,0.0,-0.075588435,0.39483184
MTF1 activates gene expression,1.7913666e-07,3.0,1.7913666e-07,-0.07548382,0.30354398
Macroautophagy,6.193827e-07,42.0,6.193827e-07,-0.07522673,-1.477901
Major pathway of rRNA processing in the nucleolus and cytosol,3.735663e-05,88.0,3.735663e-05,-0.05377334,-3.5632834
Meiotic recombination,0.0011261234,20.0,0.0011261234,0.582032,0.018406125
Meiotic synapsis,0.000299895,24.0,0.000299895,0.099540785,-0.52497345
Melanin biosynthesis,0.0,1.0,0.0,-0.075588435,0.39483184
Metabolism of Angiotensinogen to Angiotensins,3.1209668e-06,3.0,3.1209668e-06,-0.07376589,0.30482808
Metabolism of folate and pterines,5.2941537e-06,10.0,5.2941537e-06,-0.07249682,-0.014004327
Metabolism of ingested H2SeO4 and H2SeO3 into H2Se,1.810924e-09,4.0,1.810924e-09,-0.07558738,0.25778356
Metabolism of ingested MeSeO2H into MeSeH,6.5025643e-09,2.0,6.5025643e-09,-0.075584635,0.34915164
"Metabolism of ingested SeMet, Sec, MeSec into H2Se",1.8336399e-05,6.0,1.8336399e-05,-0.06488055,0.1744206
Metabolism of serotonin,5.3121303e-06,2.0,5.3121303e-06,-0.07248631,0.35146755
Metabolism of vitamin K,1.1271824e-08,3.0,1.1271824e-08,-0.07558185,0.30347073
Metal sequestration by antimicrobial proteins,0.0,1.0,0.0,-0.075588435,0.39483184
Metalloprotease DUBs,5.1008607e-05,17.0,5.1008607e-05,-0.045801014,-0.31383106
Metallothioneins bind metals,0.0,1.0,0.0,-0.075588435,0.39483184
Methionine salvage pathway,1.30369735e-05,6.0,1.30369735e-05,-0.06797525,0.17210741
Methylation,1.08757395e-05,9.0,1.08757395e-05,-0.069237344,0.03411503
Methylation of MeSeH for excretion,0.0,1.0,0.0,-0.075588435,0.39483184
MicroRNA (miRNA) biogenesis,7.496191e-05,16.0,7.496191e-05,-0.031813044,-0.2576925
Mineralocorticoid biosynthesis,0.0,1.0,0.0,-0.075588435,0.39483184
Miscellaneous substrates,0.0002862133,3.0,0.0002862133,0.0915511,0.42839757
Miscellaneous transport and binding events,8.18332e-06,15.0,8.18332e-06,-0.07080963,-0.24115823
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta),9.786851e-08,10.0,9.786851e-08,-0.07553128,-0.0162725
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha),1.0266227e-05,11.0,1.0266227e-05,-0.06959328,-0.05751702
Misspliced GSK3beta mutants stabilize beta-catenin,1.412889e-07,11.0,1.412889e-07,-0.07550593,-0.061936546
Misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling,2.2580542e-07,3.0,2.2580542e-07,-0.075456575,0.30356437
Mitochondrial ABC transporters,2.5028312e-05,4.0,2.5028312e-05,-0.060972687,0.2687076
Mitochondrial protein import,1.8122003e-06,36.0,1.8122003e-06,-0.07453017,-1.2032822
Mitochondrial tRNA aminoacylation,3.9286584e-05,15.0,3.9286584e-05,-0.05264631,-0.2275817
Mitochondrial transcription initiation,3.3633572e-05,3.0,3.3633572e-05,-0.055947486,0.31814682
Mitochondrial transcription termination,9.855322e-06,2.0,9.855322e-06,-0.069833234,0.35345066
Mitochondrial translation elongation,8.887675e-06,50.0,8.887675e-06,-0.07039831,-1.8397558
Mitochondrial translation initiation,0.00012132848,50.0,0.00012132848,-0.0047364305,-1.7906756
Mitochondrial translation termination,2.5397583e-05,50.0,2.5397583e-05,-0.06075705,-1.8325493
Mitotic Anaphase,2.5963357e-06,104.0,2.4964766e-08,-0.07557385,-4.3093843
Mitotic Metaphase/Anaphase Transition,2.7850804e-13,2.0,2.7850804e-13,-0.075588435,0.3491488
Molecules associated with elastic fibres,7.089141e-05,11.0,7.089141e-05,-0.03419009,-0.031054208
Molybdenum cofactor biosynthesis,5.6770855e-08,4.0,5.6770855e-08,-0.07555528,0.25780758
Mtb iron assimilation by chelation,0.0,1.0,0.0,-0.075588435,0.39483184
Multifunctional anion exchangers,1.856859e-06,2.0,1.856859e-06,-0.07450409,0.3499593
MyD88 deficiency (TLR2/4),3.582199e-07,4.0,3.582199e-07,-0.07537924,0.25793913
MyD88 deficiency (TLR5),1.957094e-08,2.0,1.957094e-08,-0.075577006,0.34915736
MyD88 dependent cascade initiated on endosome,4.6941488e-05,54.0,4.6941488e-05,-0.048176084,-2.0058775
MyD88-independent TLR4 cascade ,0.00061535434,63.0,0.00061535434,0.2837591,-2.168913
Myoclonic epilepsy of Lafora,2.0848105e-09,7.0,2.0848105e-09,-0.07558722,0.120734714
N-glycan antennae elongation in the medial/trans-Golgi,2.0493517e-05,12.0,2.0493517e-05,-0.063620865,-0.098735824
N-glycan trimming and elongation in the cis-Golgi,4.3597298e-05,4.0,4.3597298e-05,-0.050128985,0.27681294
NADE modulates death signalling,2.8399953e-07,5.0,2.8399953e-07,-0.075422585,0.21222377
NADPH regeneration,3.8958312e-08,2.0,3.8958312e-08,-0.07556568,0.3491658
NCAM1 interactions,2.6905045e-10,13.0,2.6905045e-10,-0.07558828,-0.15336412
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,5.912642e-05,10.0,5.912642e-05,-0.041060466,0.009493392
NF-kB is activated and signals survival,3.5432797e-07,11.0,3.5432797e-07,-0.07538152,-0.061843555
NFG and proNGF binds to p75NTR,2.0536977e-06,2.0,2.0536977e-06,-0.07438914,0.35004523
NGF processing,2.2484153e-06,3.0,2.2484153e-06,-0.07427543,0.30444723
NIK-->noncanonical NF-kB signaling,1.1703526e-06,36.0,1.1703526e-06,-0.074904986,-1.2035624
NOD1/2 Signaling Pathway,0.0001596949,25.0,0.0001596949,0.01766835,-0.63185364
NOSIP mediated eNOS trafficking,0.0,1.0,0.0,-0.075588435,0.39483184
NOSTRIN mediated eNOS trafficking,1.8583998e-07,4.0,1.8583998e-07,-0.07547991,0.2578639
NOTCH1 Intracellular Domain Regulates Transcription,9.0277705e-09,31.0,9.0277705e-09,-0.07558317,-0.9756543
NOTCH2 Activation and Transmission of Signal to the Nucleus,1.7267496e-08,16.0,1.7267496e-08,-0.07557835,-0.29040572
NOTCH2 intracellular domain regulates transcription,1.3488934e-08,8.0,1.3488934e-08,-0.07558055,0.07505668
NOTCH3 Intracellular Domain Regulates Transcription,6.2505706e-07,15.0,6.2505706e-07,-0.075223416,-0.24445741
NOTCH4 Activation and Transmission of Signal to the Nucleus,1.398249e-08,8.0,1.398249e-08,-0.07558027,0.075056896
NOTCH4 Intracellular Domain Regulates Transcription,2.2435435e-07,9.0,2.2435435e-07,-0.07545741,0.02946572
NR1D1 (REV-ERBA) represses gene expression,1.5615734e-10,3.0,1.5615734e-10,-0.07558834,0.30346587
NRAGE signals death through JNK,3.314871e-06,32.0,3.314871e-06,-0.073652655,-1.0198942
NRIF signals cell death from the nucleus,2.5382855e-08,13.0,2.5382855e-08,-0.075573616,-0.15335314
NS1 Mediated Effects on Host Pathways,1.5825688e-07,29.0,1.5825688e-07,-0.07549602,-0.8842232
NTF3 activates NTRK2 (TRKB) signaling,0.0,1.0,0.0,-0.075588435,0.39483184
NTF3 activates NTRK3 signaling,0.0,1.0,0.0,-0.075588435,0.39483184
NTF4 activates NTRK2 (TRKB) signaling,0.0,1.0,0.0,-0.075588435,0.39483184
NTRK3 as a dependence receptor,4.96833e-09,3.0,4.96833e-09,-0.07558554,0.30346796
Na+/Cl- dependent neurotransmitter transporters,4.848275e-07,4.0,4.848275e-07,-0.07530531,0.2579944
Nectin/Necl  trans heterodimerization,1.6672553e-07,2.0,1.6672553e-07,-0.07549107,0.3492216
Neddylation,0.0003375539,141.0,2.3939995e-06,-0.074190415,-5.853447
Negative regulation of FGFR1 signaling,2.8818312e-09,18.0,2.8818312e-09,-0.07558675,-0.38177797
Negative regulation of FGFR2 signaling,2.1926273e-06,18.0,2.1926273e-06,-0.07430801,-0.38082218
Negative regulation of FGFR3 signaling,1.0452664e-08,18.0,1.0452664e-08,-0.07558233,-0.38177466
Negative regulation of FGFR4 signaling,2.8404262e-08,19.0,2.8404262e-08,-0.07557184,-0.42744982
Negative regulation of MAPK pathway,3.5048804e-06,25.0,3.5048804e-06,-0.073541686,-0.7000303
Negative regulation of MET activity,8.094039e-09,17.0,8.094039e-09,-0.07558371,-0.3360927
Negative regulation of NOTCH4 signaling,1.5958225e-08,35.0,1.5958225e-08,-0.07557911,-1.1583833
Negative regulation of TCF-dependent signaling by DVL-interacting proteins,7.101774e-07,4.0,7.101774e-07,-0.07517371,0.25809276
Negative regulation of TCF-dependent signaling by WNT ligand antagonists,1.629154e-05,4.0,1.629154e-05,-0.06607469,0.264894
Negative regulation of activity of TFAP2 (AP-2) family transcription factors,3.3251396e-05,6.0,3.3251396e-05,-0.05617067,0.18093097
Negative regulators of DDX58/IFIH1 signaling,0.00046538154,28.0,0.00046538154,0.1961797,-0.6354708
Nephrin family interactions,3.8535277e-06,12.0,3.8535277e-06,-0.0733381,-0.105999164
Netrin mediated repulsion signals,5.4529405e-08,4.0,5.4529405e-08,-0.07555659,0.25780657
Neurexins and neuroligins,1.1103482e-05,17.0,1.1103482e-05,-0.06910435,-0.33124956
Neurofascin interactions,2.8390149e-08,4.0,2.8390149e-08,-0.07557185,0.25779518
Neurophilin interactions with VEGF and VEGFR,0.0,1.0,0.0,-0.075588435,0.39483184
Neutrophil degranulation,0.00059909554,239.0,2.5066759e-06,-0.07412462,-10.216218
Nicotinamide salvaging,0.0007210535,7.0,0.0007210535,0.34548408,0.43547276
NoRC negatively regulates rRNA expression,0.055536557,40.0,0.055536557,32.356007,22.85483
Noncanonical activation of NOTCH3,7.772161e-09,6.0,7.772161e-09,-0.0755839,0.16642018
Nonhomologous End-Joining (NHEJ),0.0030679854,25.0,0.0030679854,1.7160183,0.6376115
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC),0.00010610938,51.0,0.00010610938,-0.0136239035,-1.8430018
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC),1.31776205e-05,36.0,1.31776205e-05,-0.06789312,-1.1983213
Norepinephrine Neurotransmitter Release Cycle,5.0959425e-05,6.0,5.0959425e-05,-0.045829736,0.18866052
Notch-HLH transcription pathway,0.00050772226,12.0,0.00050772226,0.22090535,0.11393888
NrCAM interactions,9.599244e-10,4.0,9.599244e-10,-0.07558787,0.2577832
Nuclear Envelope Breakdown,1.0040909e-05,33.0,1.0040909e-05,-0.06972486,-1.0626415
Nuclear Events (kinase and transcription factor activation),1.6819972e-06,19.0,1.6819972e-06,-0.0746062,-0.42672804
Nuclear Receptor transcription pathway,7.6160054e-06,28.0,7.6160054e-06,-0.07114092,-0.8352848
Nuclear signaling by ERBB4,8.9542496e-08,13.0,8.9542496e-08,-0.07553615,-0.15332514
Nucleotide-like (purinergic) receptors,3.5608854e-09,4.0,3.5608854e-09,-0.07558635,0.25778434
O-glycosylation of TSR domain-containing proteins,1.827848e-08,3.0,1.827848e-08,-0.07557776,0.30347377
Olfactory Signaling Pathway,5.0820198e-08,36.0,5.0820198e-08,-0.07555876,-1.2040511
Oncogene Induced Senescence,0.00014628778,23.0,0.00014628778,0.009839017,-0.5463398
Opioid Signalling,5.2195924e-07,41.0,5.2195924e-07,-0.075283624,-1.4322604
Opsins,1.2479078e-08,3.0,1.2479078e-08,-0.07558114,0.30347124
Orc1 removal from chromatin,3.297626e-08,46.0,3.297626e-08,-0.075569175,-1.6608889
Organic anion transport,2.8463949e-06,2.0,2.8463949e-06,-0.073926225,0.35039127
Organic anion transporters,2.1756743e-09,2.0,2.1756743e-09,-0.07558716,0.34914976
Organic cation transport,8.14236e-08,2.0,8.14236e-08,-0.075540885,0.34918436
Other interleukin signaling,6.601189e-07,14.0,6.601189e-07,-0.07520294,-0.19875908
Other semaphorin interactions,2.793588e-05,6.0,2.793588e-05,-0.05927476,0.17861077
Ovarian tumor domain proteases,3.6301695e-05,25.0,3.6301695e-05,-0.054389387,-0.6857146
Oxidative Stress Induced Senescence,0.00030850948,47.0,0.00030850948,0.104571365,-1.5719223
Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha,2.0391204e-07,3.0,2.0391204e-07,-0.07546935,0.3035548
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.00030306113,37.0,0.00030306113,0.1013897,-1.1174705
PAOs oxidise polyamines to amines,0.0,1.0,0.0,-0.075588435,0.39483184
PCNA-Dependent Long Patch Base Excision Repair,6.0439316e-07,15.0,6.0439316e-07,-0.075235486,-0.24446642
PD-1 signaling,0.00015834061,6.0,0.00015834061,0.016877487,0.23553225
PECAM1 interactions,7.160217e-07,10.0,7.160217e-07,-0.07517029,-0.016002672
PI and PC transport between ER and Golgi membranes,9.927112e-09,3.0,9.927112e-09,-0.07558264,0.30347013
PI3K events in ERBB2 signaling,8.406144e-09,8.0,8.406144e-09,-0.07558352,0.07505447
PI3K events in ERBB4 signaling,3.3774246e-08,5.0,3.3774246e-08,-0.075568706,0.21211453
PI3K/AKT activation,6.868831e-07,7.0,6.868831e-07,-0.07518732,0.121033624
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",6.948671e-05,46.0,6.948671e-05,-0.035010386,-1.6305724
PIPs transport between Golgi and plasma membranes,0.0,1.0,0.0,-0.075588435,0.39483184
PIPs transport between early and late endosome membranes,0.0,1.0,0.0,-0.075588435,0.39483184
PIPs transport between early endosome and Golgi membranes,0.0,1.0,0.0,-0.075588435,0.39483184
PIPs transport between late endosome and Golgi membranes,0.0,1.0,0.0,-0.075588435,0.39483184
PIPs transport between plasma and early endosome membranes,0.0,1.0,0.0,-0.075588435,0.39483184
PIWI-interacting RNA (piRNA) biogenesis,6.2035164e-05,12.0,6.2035164e-05,-0.039361853,-0.08060295
PKA activation in glucagon signalling,1.0291176e-06,7.0,1.0291176e-06,-0.07498746,0.12118301
PKA-mediated phosphorylation of key metabolic factors,7.3558806e-07,2.0,7.3558806e-07,-0.07515887,0.3494699
PKMTs methylate histone lysines,1.6894452e-05,32.0,1.6894452e-05,-0.06572261,-1.0139668
PLC-gamma1 signalling,9.439214e-10,2.0,9.439214e-10,-0.07558788,0.34914923
PLCG1 events in ERBB2 signaling,4.5894765e-08,4.0,4.5894765e-08,-0.07556163,0.2578028
POLB-Dependent Long Patch Base Excision Repair,7.307872e-09,7.0,7.307872e-09,-0.075584166,0.12073698
"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",2.5981826e-08,4.0,2.5981826e-08,-0.075573266,0.2577941
"POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation",2.6263178e-09,3.0,2.6263178e-09,-0.0755869,0.30346695
PP2A-mediated dephosphorylation of key metabolic factors,6.202642e-07,5.0,6.202642e-07,-0.07522622,0.21237054
PPARA activates gene expression,2.5272195e-07,20.0,2.5272195e-07,-0.075440854,-0.47303495
PRC2 methylates histones and DNA,0.00048649844,19.0,0.00048649844,0.2085113,-0.21510631
PTEN Loss of Function in Cancer,0.0,1.0,0.0,-0.075588435,0.39483184
PTK6 Activates STAT3,1.5994404e-10,3.0,1.5994404e-10,-0.07558834,0.30346587
PTK6 Down-Regulation,1.7589669e-07,3.0,1.7589669e-07,-0.075485714,0.30354258
PTK6 Expression,5.5170364e-08,5.0,5.5170364e-08,-0.07555622,0.21212387
PTK6 Regulates Cell Cycle,1.4739443e-08,7.0,1.4739443e-08,-0.07557982,0.12074024
PTK6 Regulates Proteins Involved in RNA Processing,7.005515e-06,4.0,7.005515e-06,-0.07149743,0.26084068
"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases",9.3525095e-08,11.0,9.3525095e-08,-0.075533815,-0.061957393
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1,1.16078205e-08,9.0,1.16078205e-08,-0.075581655,0.029372854
PTK6 promotes HIF1A stabilization,9.067716e-08,4.0,9.067716e-08,-0.07553548,0.25782236
Packaging Of Telomere Ends,1.0913401e-06,12.0,1.0913401e-06,-0.07495113,-0.107204854
Paradoxical activation of RAF signaling by kinase inactive BRAF,4.007279e-08,23.0,4.007279e-08,-0.07556503,-0.61017674
Passive transport by Aquaporins,3.1182847e-09,3.0,3.1182847e-09,-0.07558662,0.30346715
Peptide chain elongation,8.271551e-06,32.0,8.271551e-06,-0.07075811,-1.0177307
Peptide ligand-binding receptors,9.419393e-08,31.0,9.419393e-08,-0.07553343,-0.9756172
Phase 0 - rapid depolarisation,2.6621308e-08,10.0,2.6621308e-08,-0.07557289,-0.016303599
Phase 1 - inactivation of fast Na+ channels,4.2299965e-07,5.0,4.2299965e-07,-0.07534142,0.21228443
Phase 2 - plateau phase,4.452717e-08,11.0,4.452717e-08,-0.07556243,-0.061978783
Phase 3 - rapid repolarisation,8.970394e-08,4.0,8.970394e-08,-0.07553605,0.25782192
Phase 4 - resting membrane potential,5.994116e-08,5.0,5.994116e-08,-0.07555343,0.21212596
Phenylalanine and tyrosine catabolism,5.629813e-05,5.0,5.629813e-05,-0.0427121,0.23667386
Phenylketonuria,0.0,1.0,0.0,-0.075588435,0.39483184
Phosphate bond hydrolysis by NTPDase proteins,4.7159259e-07,5.0,4.7159259e-07,-0.07531303,0.21230565
Phosphate bond hydrolysis by NUDT proteins,4.2179463e-06,6.0,4.2179463e-06,-0.07312529,0.16825792
Phosphorylation of CD3 and TCR zeta chains,5.6782977e-05,6.0,5.6782977e-05,-0.042428967,0.19120248
Physiological factors,4.502336e-10,2.0,4.502336e-10,-0.07558817,0.34914902
Pink/Parkin Mediated Mitophagy,7.2826165e-06,16.0,7.2826165e-06,-0.071335614,-0.2872344
Plasmalogen biosynthesis,7.2584776e-08,3.0,7.2584776e-08,-0.07554605,0.3034975
Platelet Adhesion to exposed collagen,7.189305e-08,7.0,7.189305e-08,-0.07554645,0.12076517
Platelet degranulation ,6.268366e-05,54.0,6.268366e-05,-0.03898315,-1.9990059
Platelet sensitization by LDL,1.1317546e-06,10.0,1.1317546e-06,-0.074927524,-0.015821204
Polo-like kinase mediated events,3.2524053e-07,7.0,3.2524053e-07,-0.075398505,0.12087575
Polymerase switching,1.2088598e-08,11.0,1.2088598e-08,-0.07558137,-0.061992943
Post NMDA receptor activation events,4.986708e-05,17.0,4.986708e-05,-0.04646763,-0.31432933
Post-chaperonin tubulin folding pathway,2.0692925e-08,7.0,2.0692925e-08,-0.07557635,0.120742835
Post-transcriptional silencing by small RNAs,2.7029742e-07,7.0,2.7029742e-07,-0.07543059,0.120851785
Post-translational protein phosphorylation,1.71688e-05,36.0,1.71688e-05,-0.0655624,-1.1965792
Potassium transport channels,6.644822e-07,3.0,6.644822e-07,-0.075200394,0.30375585
Pre-NOTCH Processing in Golgi,2.555942e-07,7.0,2.555942e-07,-0.07543918,0.12084536
Pre-NOTCH Processing in the Endoplasmic Reticulum,3.4102476e-10,6.0,3.4102476e-10,-0.075588234,0.16641694
Pre-NOTCH Transcription and Translation,3.884393e-06,34.0,3.884393e-06,-0.073320076,-1.1110117
Prefoldin mediated transfer of substrate  to CCT/TriC,2.8402732e-07,14.0,2.8402732e-07,-0.07542257,-0.19892325
Pregnenolone biosynthesis,3.6406288e-08,6.0,3.6406288e-08,-0.07556717,0.16643268
Presynaptic depolarization and calcium channel opening,4.7947424e-06,7.0,4.7947424e-06,-0.072788455,0.122826695
Presynaptic function of Kainate receptors,1.128017e-07,12.0,1.128017e-07,-0.07552256,-0.10763198
Processing of DNA double-strand break ends,0.00076383003,44.0,0.00076383003,0.3704642,-1.2361264
Processing of Intronless Pre-mRNAs,7.0597036e-07,14.0,7.0597036e-07,-0.075176165,-0.19873908
Processing of SMDT1,6.8396257e-06,9.0,6.8396257e-06,-0.07159431,0.03235328
Processive synthesis on the lagging strand,1.7562743e-06,11.0,1.7562743e-06,-0.074562825,-0.061231606
Prolactin receptor signaling,4.2657907e-06,9.0,4.2657907e-06,-0.07309735,0.031229803
Proline catabolism,0.0,1.0,0.0,-0.075588435,0.39483184
Propionyl-CoA catabolism,4.987973e-07,5.0,4.987973e-07,-0.075297154,0.21231753
Prostacyclin signalling through prostacyclin receptor,8.5197274e-07,11.0,8.5197274e-07,-0.07509091,-0.061626334
Protein methylation,4.289156e-07,8.0,4.289156e-07,-0.07533796,0.07523802
Protein repair,6.930327e-06,4.0,6.930327e-06,-0.07154135,0.26080787
Proton-coupled monocarboxylate transport,0.0001493765,2.0,0.0001493765,0.01164273,0.4143515
Proton-coupled neutral amino acid transporters,0.0,1.0,0.0,-0.075588435,0.39483184
Proton/oligopeptide cotransporters,1.0036006e-06,2.0,1.0036006e-06,-0.07500236,0.3495869
Purine ribonucleoside monophosphate biosynthesis,2.1784782e-08,10.0,2.1784782e-08,-0.07557571,-0.016305706
Purine salvage,1.384143e-05,8.0,1.384143e-05,-0.06750547,0.08109256
Pyrimidine biosynthesis,4.0963322e-10,2.0,4.0963322e-10,-0.0755882,0.34914902
Pyrimidine catabolism,2.464913e-08,3.0,2.464913e-08,-0.07557404,0.30347657
Pyrimidine salvage,9.51484e-06,6.0,9.51484e-06,-0.07003207,0.17057002
Pyrophosphate hydrolysis,0.0,2.0,0.0,-0.075588435,0.3491488
RA biosynthesis pathway,1.2438556e-09,10.0,1.2438556e-09,-0.07558771,-0.016314674
RAB GEFs exchange GTP for GDP on RABs,0.00028800423,63.0,0.00028800423,0.09259695,-2.3118007
RAB geranylgeranylation,0.00011213461,42.0,0.00011213461,-0.010105361,-1.4292247
RAF activation,1.7104269e-06,18.0,1.7104269e-06,-0.074589595,-0.38103265
RAS signaling downstream of NF1 loss-of-function variants,4.039425e-07,5.0,4.039425e-07,-0.07535254,0.21227613
RET signaling,0.00010769225,20.0,0.00010769225,-0.0126995575,-0.42613772
RHO GTPases Activate Formins,3.3646047e-05,66.0,3.3646047e-05,-0.0559402,-2.559877
RHO GTPases Activate NADPH Oxidases,1.0628395e-06,5.0,1.0628395e-06,-0.074967764,0.21256374
RHO GTPases Activate ROCKs,1.1371737e-05,11.0,1.1371737e-05,-0.068947695,-0.05703447
RHO GTPases Activate Rhotekin and Rhophilins,3.0251113e-06,6.0,3.0251113e-06,-0.073821865,0.16773725
RHO GTPases Activate WASPs and WAVEs,4.060291e-05,29.0,4.060291e-05,-0.05187761,-0.8665692
RHO GTPases activate CIT,3.6361365e-07,9.0,3.6361365e-07,-0.07537609,0.029526502
RHO GTPases activate IQGAPs,1.3063963e-07,11.0,1.3063963e-07,-0.07551215,-0.061941195
RHO GTPases activate KTN1,8.4002625e-07,10.0,8.4002625e-07,-0.07509789,-0.015948549
RHO GTPases activate PAKs,4.1109876e-09,13.0,4.1109876e-09,-0.07558603,-0.15336242
RHO GTPases regulate CFTR trafficking,8.228493e-12,2.0,8.228493e-12,-0.07558843,0.3491488
RIP-mediated NFkB activation via ZBP1,0.00061579415,10.0,0.00061579415,0.28401592,0.25247812
RMTs methylate histone arginines,3.260732e-05,27.0,3.260732e-05,-0.056546785,-0.77869326
RNA Pol II CTD phosphorylation and interaction with CE,7.745646e-06,21.0,7.745646e-06,-0.07106522,-0.51544726
RNA Polymerase I Chain Elongation,2.2467232e-06,19.0,2.2467232e-06,-0.07427642,-0.42648152
RNA Polymerase I Promoter Escape,1.3123037e-05,19.0,1.3123037e-05,-0.067925,-0.42173404
RNA Polymerase I Promoter Opening,6.949557e-07,3.0,6.949557e-07,-0.0751826,0.30376914
RNA Polymerase I Transcription Initiation,2.3623054e-06,21.0,2.3623054e-06,-0.07420892,-0.5177971
RNA Polymerase I Transcription Termination,0.0015637805,20.0,0.0015637805,0.83761,0.20944291
RNA Polymerase II Pre-transcription Events,6.8137655e-05,59.0,6.8137655e-05,-0.035798192,-2.2250404
RNA Polymerase II Promoter Escape,2.6886448e-07,35.0,2.6886448e-07,-0.07543143,-1.1582729
RNA Polymerase II Transcription Initiation,4.8121703e-05,35.0,4.8121703e-05,-0.04748688,-1.1373851
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening,1.1356606e-05,35.0,1.1356606e-05,-0.06895653,-1.1534331
RNA Polymerase III Abortive And Retractive Initiation,5.893832e-07,26.0,5.893832e-07,-0.075244255,-0.746986
RNA Polymerase III Chain Elongation,7.5899675e-07,14.0,7.5899675e-07,-0.0751452,-0.19871594
RNA Polymerase III Transcription Initiation From Type 1 Promoter,3.6376653e-07,21.0,3.6376653e-07,-0.075376004,-0.5186694
RNA Polymerase III Transcription Initiation From Type 2 Promoter,1.0853518e-06,21.0,1.0853518e-06,-0.07495462,-0.5183545
RNA Polymerase III Transcription Initiation From Type 3 Promoter,1.0632017e-05,20.0,1.0632017e-05,-0.06937967,-0.46850437
RNA Polymerase III Transcription Termination,1.0060978e-06,14.0,1.0060978e-06,-0.0750009,-0.19860806
RNA polymerase II transcribes snRNA genes,8.6963875e-05,47.0,8.6963875e-05,-0.024804274,-1.6686267
RNF mutants show enhanced WNT signaling and proliferation,3.6591705e-11,2.0,3.6591705e-11,-0.075588405,0.3491488
ROBO receptors bind AKAP5,8.96432e-05,4.0,8.96432e-05,-0.023239631,0.29691193
RORA activates gene expression,5.50905e-08,4.0,5.50905e-08,-0.07555626,0.25780684
"ROS, RNS production in phagocytes",1.0708341e-05,14.0,1.0708341e-05,-0.0693351,-0.19437304
RPIA deficiency: failed conversion of R5P to RU5P,0.0,1.0,0.0,-0.075588435,0.39483184
RPIA deficiency: failed conversion of RU5P to R5P,0.0,1.0,0.0,-0.075588435,0.39483184
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),1.6953678e-07,3.0,1.6953678e-07,-0.07548943,0.30353978
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,1.2027434e-05,25.0,1.2027434e-05,-0.06856479,-0.6963103
RUNX1 regulates estrogen receptor mediated transcription,8.543519e-07,7.0,8.543519e-07,-0.075089514,0.12110672
RUNX1 regulates expression of components of tight junctions,5.819506e-08,4.0,5.819506e-08,-0.07555445,0.25780818
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,4.1247035e-06,33.0,4.1247035e-06,-0.07317974,-1.0652238
RUNX1 regulates transcription of genes involved in BCR signaling,1.3983962e-08,5.0,1.3983962e-08,-0.07558027,0.2121059
RUNX1 regulates transcription of genes involved in WNT signaling,1.1064979e-07,5.0,1.1064979e-07,-0.075523816,0.21214809
RUNX1 regulates transcription of genes involved in differentiation of HSCs,7.758903e-06,50.0,7.758903e-06,-0.071057476,-1.8402486
RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,2.3590806e-07,6.0,2.3590806e-07,-0.07545067,0.16651976
RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,6.386282e-06,6.0,6.386282e-06,-0.07185905,0.1692044
RUNX1 regulates transcription of genes involved in interleukin signaling,2.7637084e-08,4.0,2.7637084e-08,-0.0755723,0.25779486
RUNX2 regulates bone development,3.5632197e-06,16.0,3.5632197e-06,-0.07350762,-0.2888579
RUNX2 regulates genes involved in cell migration,1.8611527e-05,6.0,1.8611527e-05,-0.064719886,0.1745407
RUNX2 regulates genes involved in differentiation of myeloid cells,1.8864074e-07,4.0,1.8864074e-07,-0.07547828,0.25786513
RUNX3 Regulates Immune Response and Cell Migration,7.665752e-07,3.0,7.665752e-07,-0.075140774,0.3038004
RUNX3 regulates BCL2L11 (BIM) transcription,0.0003549758,4.0,0.0003549758,0.13170624,0.4127293
RUNX3 regulates CDKN1A transcription,0.00033891905,6.0,0.00033891905,0.1223296,0.3143545
RUNX3 regulates NOTCH signaling,3.7449576e-05,11.0,3.7449576e-05,-0.053719066,-0.04565153
RUNX3 regulates RUNX1-mediated transcription,4.5489884e-05,3.0,4.5489884e-05,-0.049023777,0.32332206
RUNX3 regulates WNT signaling,8.181931e-05,7.0,8.181931e-05,-0.02780854,0.15644781
RUNX3 regulates YAP1-mediated transcription,4.0740912e-07,2.0,4.0740912e-07,-0.075350516,0.34932664
RUNX3 regulates p14-ARF,1.9995563e-05,5.0,1.9995563e-05,-0.063911654,0.22082782
Rap1 signalling,4.291177e-05,8.0,4.291177e-05,-0.050529312,0.09378173
Receptor Mediated Mitophagy,1.6558455e-05,10.0,1.6558455e-05,-0.06591882,-0.009087473
Receptor-type tyrosine-protein phosphatases,1.095446e-05,7.0,1.095446e-05,-0.069191374,0.1255154
Recognition and association of DNA glycosylase with site containing an affected purine,2.7233595e-09,2.0,2.7233595e-09,-0.07558684,0.34915
Recognition and association of DNA glycosylase with site containing an affected pyrimidine,2.0266734e-06,8.0,2.0266734e-06,-0.07440492,0.07593544
Recognition of DNA damage by PCNA-containing replication complex,0.00025469478,22.0,0.00025469478,0.07314528,-0.45333728
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.00024383976,30.0,0.00024383976,0.066806294,-0.8235395
Recruitment of NuMA to mitotic centrosomes,1.2136074e-08,55.0,1.2136074e-08,-0.07558134,-2.072045
Recycling of bile acids and salts,6.898089e-06,5.0,6.898089e-06,-0.07156017,0.2151108
Recycling of eIF2:GDP,8.367742e-07,8.0,8.367742e-07,-0.07509978,0.07541605
Recycling pathway of L1,1.2337817e-07,18.0,1.2337817e-07,-0.07551639,-0.3817254
Reduction of cytosolic Ca++ levels,9.353181e-09,4.0,9.353181e-09,-0.075582966,0.25778687
Reelin signalling pathway,3.0523603e-07,3.0,3.0523603e-07,-0.07541018,0.30359903
Regulated proteolysis of p75NTR,9.268222e-08,10.0,9.268222e-08,-0.07553431,-0.01627476
Regulation by TREX1,0.0,1.0,0.0,-0.075588435,0.39483184
Regulation by c-FLIP,4.8217524e-05,9.0,4.8217524e-05,-0.04743092,0.050414674
Regulation of Complement cascade,0.00080720714,7.0,0.00080720714,0.39579508,0.4730787
Regulation of FZD by ubiquitination,5.2690467e-08,8.0,5.2690467e-08,-0.075557664,0.0750738
Regulation of Glucokinase by Glucokinase Regulatory Protein,1.0085204e-07,23.0,1.0085204e-07,-0.075529546,-0.6101502
Regulation of HSF1-mediated heat shock response,4.705157e-05,45.0,4.705157e-05,-0.048111804,-1.5946823
Regulation of IFNA signaling,8.6377026e-05,10.0,8.6377026e-05,-0.025146976,0.021388244
Regulation of IFNG signaling,0.000315863,11.0,0.000315863,0.10886559,0.07587558
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1.6980175e-06,36.0,1.6980175e-06,-0.074596845,-1.2033321
Regulation of KIT signaling,0.00048732918,12.0,0.00048732918,0.20899642,0.10503735
Regulation of PAK-2p34 activity by PS-GAP/RHG10,8.181701e-08,3.0,8.181701e-08,-0.075540654,0.30350152
Regulation of PLK1 Activity at G2/M Transition,5.5491895e-05,59.0,5.5491895e-05,-0.043182917,-2.2305603
Regulation of PTEN gene transcription,1.2393292e-05,36.0,1.2393292e-05,-0.06835114,-1.1986636
Regulation of PTEN localization,1.3097742e-05,8.0,1.3097742e-05,-0.067939766,0.080767944
Regulation of PTEN mRNA translation,8.068598e-05,10.0,8.068598e-05,-0.028470365,0.01890411
Regulation of PTEN stability and activity,3.3928813e-05,44.0,3.3928813e-05,-0.05577508,-1.5547274
Regulation of RAS by GAPs,5.162306e-07,42.0,5.162306e-07,-0.07528697,-1.4779459
Regulation of RUNX1 Expression and Activity,2.1822909e-05,17.0,2.1822909e-05,-0.062844545,-0.32657057
Regulation of RUNX2 expression and activity,2.6867258e-06,42.0,2.6867258e-06,-0.07401947,-1.4769986
Regulation of RUNX3 expression and activity,0.000119511256,32.0,0.000119511256,-0.0057976306,-0.96917474
Regulation of TLR by endogenous ligand,7.83165e-09,5.0,7.83165e-09,-0.07558386,0.2121032
Regulation of TNFR1 signaling,1.6010675e-08,22.0,1.6010675e-08,-0.075579084,-0.5645042
Regulation of TP53 Activity,1.4480046e-05,110.0,1.3163678e-07,-0.07551156,-4.578295
Regulation of actin dynamics for phagocytic cup formation,0.0004977547,42.0,0.0004977547,0.21508463,-1.260902
Regulation of activated PAK-2p34 by proteasome mediated degradation,7.3580924e-07,31.0,7.3580924e-07,-0.075158745,-0.9753371
Regulation of commissural axon pathfinding by SLIT and ROBO,7.382375e-13,2.0,7.382375e-13,-0.075588435,0.3491488
Regulation of cortical dendrite branching,0.0,1.0,0.0,-0.075588435,0.39483184
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,1.4963006e-05,6.0,1.4963006e-05,-0.066850506,0.17294812
Regulation of expression of SLITs and ROBOs,0.00042350005,76.0,0.00042350005,0.17172222,-2.8465364
Regulation of gene expression by Hypoxia-inducible Factor,1.0173273e-05,7.0,1.0173273e-05,-0.069647565,0.12517442
Regulation of gene expression in early pancreatic precursor cells,0.0,1.0,0.0,-0.075588435,0.39483184
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells,0.0,1.0,0.0,-0.075588435,0.39483184
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,4.8864707e-10,2.0,4.8864707e-10,-0.075588144,0.34914902
Regulation of ornithine decarboxylase (ODC),2.2537622e-05,31.0,2.2537622e-05,-0.062427174,-0.96582067
Regulation of pyruvate dehydrogenase (PDH) complex,5.0394988e-08,9.0,5.0394988e-08,-0.075559005,0.029389782
Regulation of signaling by CBL,7.305958e-06,17.0,7.305958e-06,-0.07132198,-0.3329072
Regulation of signaling by NODAL,3.8026592e-05,3.0,3.8026592e-05,-0.053382102,0.32006437
Regulation of thyroid hormone activity,5.0139074e-06,2.0,5.0139074e-06,-0.07266047,0.3513374
Release of Hh-Np from the secreting cell,2.4329337e-08,3.0,2.4329337e-08,-0.07557423,0.30347642
Release of apoptotic factors from the mitochondria,3.6127042e-06,3.0,3.6127042e-06,-0.07347873,0.3050427
Removal of aminoterminal propeptides from gamma-carboxylated proteins,1.1467141e-06,2.0,1.1467141e-06,-0.074918784,0.34964934
Repression of WNT target genes,7.980781e-06,8.0,7.980781e-06,-0.07092791,0.078534395
Resolution of Sister Chromatid Cohesion,1.3357966e-09,57.0,1.3357966e-09,-0.07558765,-2.163416
Retinoid metabolism and transport,1.6965157e-10,13.0,1.6965157e-10,-0.07558833,-0.15336414
Retinoid metabolism disease events,0.0,1.0,0.0,-0.075588435,0.39483184
Retrograde neurotrophin signalling,2.5983377e-07,9.0,2.5983377e-07,-0.0754367,0.02948121
Retrograde transport at the Trans-Golgi-Network,8.070412e-06,40.0,8.070412e-06,-0.07087557,-1.3832825
Reuptake of GABA,0.0,1.0,0.0,-0.075588435,0.39483184
Reversible hydration of carbon dioxide,6.342621e-08,4.0,6.342621e-08,-0.07555139,0.25781047
Rhesus glycoproteins mediate ammonium transport.,1.3246627e-07,2.0,1.3246627e-07,-0.075511076,0.34920663
Rho GTPase cycle,4.5306697e-07,67.0,4.5306697e-07,-0.07532385,-2.6200485
Ribosomal scanning and start codon recognition,5.8984274e-06,31.0,5.8984274e-06,-0.072143935,-0.9730836
Role of ABL in ROBO-SLIT signaling,3.719232e-07,5.0,3.719232e-07,-0.07537124,0.21226212
Role of LAT2/NTAL/LAB on calcium mobilization,1.01646286e-07,11.0,1.01646286e-07,-0.075529076,-0.06195385
Role of phospholipids in phagocytosis,8.629026e-05,14.0,8.629026e-05,-0.025197644,-0.16138163
Role of second messengers in netrin-1 signaling,1.2515071e-09,4.0,1.2515071e-09,-0.075587705,0.25778332
S33 mutants of beta-catenin aren't phosphorylated,2.5735902e-08,11.0,2.5735902e-08,-0.0755734,-0.06198698
S37 mutants of beta-catenin aren't phosphorylated,3.7255255e-08,11.0,3.7255255e-08,-0.07556668,-0.061981957
S45 mutants of beta-catenin aren't phosphorylated,3.0391507e-07,11.0,3.0391507e-07,-0.075410955,-0.061865557
SCF(Skp2)-mediated degradation of p27/p21,3.7209936e-06,38.0,3.7209936e-06,-0.07341549,-1.293815
SDK interactions,0.0,1.0,0.0,-0.075588435,0.39483184
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,1.0013889e-06,7.0,1.0013889e-06,-0.075003654,0.1211709
SHC-related events triggered by IGF1R,1.7263086e-07,5.0,1.7263086e-07,-0.07548762,0.21217515
SHC1 events in EGFR signaling,1.0193022e-08,6.0,1.0193022e-08,-0.07558248,0.16642123
SHC1 events in ERBB2 signaling,6.856286e-07,12.0,6.856286e-07,-0.07518805,-0.10738195
SHC1 events in ERBB4 signaling,2.5592186e-09,7.0,2.5592186e-09,-0.07558694,0.12073492
SIRT1 negatively regulates rRNA expression,0.024983741,13.0,0.024983741,14.514129,10.752007
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs,5.7671738e-08,7.0,5.7671738e-08,-0.07555476,0.120758966
SLBP independent Processing of Histone Pre-mRNAs,3.368869e-06,7.0,3.368869e-06,-0.07362112,0.12220431
SLIT2:ROBO1 increases RHOA activity,5.1348707e-07,2.0,5.1348707e-07,-0.07528857,0.34937295
SMAC-mediated apoptotic response,4.5904703e-06,6.0,4.5904703e-06,-0.07290774,0.16842052
SMAD2/3 MH2 Domain Mutants in Cancer,6.046759e-08,6.0,6.046759e-08,-0.07555313,0.16644318
SMAD2/3 Phosphorylation Motif Mutants in Cancer,4.325498e-08,5.0,4.325498e-08,-0.07556318,0.21211867
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,0.00020467429,22.0,0.00020467429,0.043934893,-0.47517115
SMAD4 MH2 Domain Mutants in Cancer,2.5077009e-08,4.0,2.5077009e-08,-0.07557379,0.25779372
SRP-dependent cotranslational protein targeting to membrane,0.00012558326,49.0,0.00012558326,-0.0022517713,-1.7431353
STAT6-mediated induction of chemokines,9.4509886e-08,3.0,9.4509886e-08,-0.07553324,0.30350706
SUMO is conjugated to E1 (UBA2:SAE1),3.091399e-07,4.0,3.091399e-07,-0.07540791,0.25791773
SUMO is proteolytically processed,1.0599353e-07,6.0,1.0599353e-07,-0.075526536,0.16646306
"SUMO is transferred from E1 to E2 (UBE2I, UBC9)",5.4728406e-07,5.0,5.4728406e-07,-0.075268835,0.21233867
SUMOylation of DNA damage response and repair proteins,1.0809058e-05,51.0,1.0809058e-05,-0.06927628,-1.8846003
SUMOylation of DNA methylation proteins,2.784928e-06,9.0,2.784928e-06,-0.07396212,0.030583408
SUMOylation of DNA replication proteins,2.4131048e-06,32.0,2.4131048e-06,-0.074179254,-1.020288
SUMOylation of RNA binding proteins,1.3408141e-05,33.0,1.3408141e-05,-0.0677585,-1.0611717
SUMOylation of SUMOylation proteins,8.6295595e-06,28.0,8.6295595e-06,-0.07054904,-0.83484244
SUMOylation of chromatin organization proteins,9.417885e-06,38.0,9.417885e-06,-0.070088685,-1.2913284
SUMOylation of immune response proteins,2.8030829e-07,11.0,2.8030829e-07,-0.07542474,-0.06187586
SUMOylation of intracellular receptors,5.5470672e-09,21.0,5.5470672e-09,-0.075585194,-0.5188258
SUMOylation of transcription cofactors,7.6170045e-06,32.0,7.6170045e-06,-0.07114034,-1.0180165
SUMOylation of transcription factors,1.2508177e-05,16.0,1.2508177e-05,-0.06828405,-0.28495345
SUMOylation of ubiquitinylation proteins,2.1483072e-06,31.0,2.1483072e-06,-0.074333884,-0.9747206
Scavenging by Class A Receptors,1.3774567e-06,7.0,1.3774567e-06,-0.07478404,0.12133507
Scavenging by Class B Receptors,6.367121e-07,3.0,6.367121e-07,-0.075216606,0.30374372
Scavenging by Class F Receptors,3.9518647e-05,5.0,3.9518647e-05,-0.052510787,0.22934963
Scavenging by Class H Receptors,7.483999e-11,2.0,7.483999e-11,-0.07558839,0.34914884
Scavenging of heme from plasma,1.1796916e-05,6.0,1.1796916e-05,-0.068699405,0.17156613
SeMet incorporation into proteins,0.00021353927,8.0,0.00021353927,0.04911176,0.16826041
Selenocysteine synthesis,1.7741573e-05,35.0,1.7741573e-05,-0.06522792,-1.150646
Sema3A PAK dependent Axon repulsion,5.115447e-06,9.0,5.115447e-06,-0.07260117,0.031600673
Sema4D induced cell migration and growth-cone collapse,0.00033648798,11.0,0.00033648798,0.12090993,0.084878355
Sema4D mediated inhibition of cell attachment and migration,5.1706943e-06,5.0,5.1706943e-06,-0.072568916,0.21435678
Senescence-Associated Secretory Phenotype (SASP),0.0005513086,35.0,0.0005513086,0.24635841,-0.91774476
Sensing of DNA Double Strand Breaks,9.966768e-06,4.0,9.966768e-06,-0.06976815,0.26213324
Serine biosynthesis,2.4659037e-05,6.0,2.4659037e-05,-0.061188333,0.17718042
Serotonin Neurotransmitter Release Cycle,2.7616366e-05,6.0,2.7616366e-05,-0.059461348,0.17847128
Serotonin and melatonin biosynthesis,0.0,1.0,0.0,-0.075588435,0.39483184
Severe congenital neutropenia type 4 (G6PC3),0.0,1.0,0.0,-0.075588435,0.39483184
Signal attenuation,5.338783e-07,6.0,5.338783e-07,-0.075276665,0.16664983
Signal regulatory protein family interactions,3.582877e-07,8.0,3.582877e-07,-0.07537921,0.07520718
Signal transduction by L1,3.225507e-07,13.0,3.225507e-07,-0.07540007,-0.15322343
Signaling by BMP,7.643071e-10,13.0,7.643071e-10,-0.07558798,-0.15336388
Signaling by BRAF and RAF fusions,3.4128736e-06,36.0,3.4128736e-06,-0.07359542,-1.2025836
Signaling by FGFR3 fusions in cancer,5.0193375e-08,9.0,5.0193375e-08,-0.075559124,0.029389696
Signaling by FGFR3 point mutants in cancer,2.2846834e-08,11.0,2.2846834e-08,-0.07557509,-0.061988242
Signaling by Hippo,3.1210963e-08,10.0,3.1210963e-08,-0.0755702,-0.01630159
Signaling by Leptin,1.813006e-06,10.0,1.813006e-06,-0.07452969,-0.015523843
Signaling by MST1,0.0,1.0,0.0,-0.075588435,0.39483184
Signaling by RAS mutants,2.1198781e-08,29.0,2.1198781e-08,-0.07557605,-0.884283
Signaling by high-kinase activity BRAF mutants,1.988393e-08,17.0,1.988393e-08,-0.07557683,-0.33608755
Signaling by moderate kinase activity BRAF mutants,3.2080596e-09,23.0,3.2080596e-09,-0.075586565,-0.61019284
Signalling to ERK5,6.661899e-08,3.0,6.661899e-08,-0.07554953,0.30349487
Signalling to ERKs,9.3817584e-07,20.0,9.3817584e-07,-0.075040564,-0.47273573
Signalling to STAT3,2.493516e-13,2.0,2.493516e-13,-0.075588435,0.3491488
Small interfering RNA (siRNA) biogenesis,2.0954426e-06,6.0,2.0954426e-06,-0.07436476,0.16733146
Smooth Muscle Contraction,7.7914103e-07,17.0,7.7914103e-07,-0.07513344,-0.33575615
"Sodium-coupled sulphate, di- and tri-carboxylate transporters",1.9469631e-07,3.0,1.9469631e-07,-0.07547474,0.30355078
Sodium/Calcium exchangers,9.5917276e-05,5.0,9.5917276e-05,-0.019575771,0.25396755
Sodium/Proton exchangers,1.339757e-06,9.0,1.339757e-06,-0.07480606,0.02995259
Sperm Motility And Taxes,2.821596e-07,2.0,2.821596e-07,-0.07542366,0.34927198
Sperm:Oocyte Membrane Binding,2.183132e-07,2.0,2.183132e-07,-0.07546095,0.3492441
Sphingolipid de novo biosynthesis,2.7390095e-06,20.0,2.7390095e-06,-0.07398894,-0.47194964
Stimulation of the cell death response by PAK-2p34,4.3297774e-09,3.0,4.3297774e-09,-0.0755859,0.3034677
Striated Muscle Contraction,0.00014911086,18.0,0.00014911086,0.011487601,-0.31669256
Sulfide oxidation to sulfate,3.9628105e-09,2.0,3.9628105e-09,-0.07558612,0.34915054
Surfactant metabolism,2.6133404e-07,9.0,2.6133404e-07,-0.07543582,0.029481862
Synaptic adhesion-like molecules,2.0794116e-05,12.0,2.0794116e-05,-0.06344532,-0.09860461
Syndecan interactions,0.00011254984,9.0,0.00011254984,-0.009862879,0.078495644
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE),2.4819753e-09,2.0,2.4819753e-09,-0.07558698,0.3491499
Synthesis of 12-eicosatetraenoic acid derivatives,6.8480904e-07,3.0,6.8480904e-07,-0.075188525,0.3037647
Synthesis of 15-eicosatetraenoic acid derivatives,3.8940048e-08,2.0,3.8940048e-08,-0.075565696,0.3491658
Synthesis of 5-eicosatetraenoic acids,3.4660445e-06,4.0,3.4660445e-06,-0.07356437,0.2592957
Synthesis of BMP,0.0,1.0,0.0,-0.075588435,0.39483184
Synthesis of CL,5.2173533e-07,2.0,5.2173533e-07,-0.07528376,0.34937656
Synthesis of Hepoxilins (HX) and Trioxilins (TrX),5.409471e-08,2.0,5.409471e-08,-0.075556844,0.3491724
"Synthesis of IP2, IP, and Ins in the cytosol",3.710192e-07,9.0,3.710192e-07,-0.07537177,0.029529735
Synthesis of IP3 and IP4 in the cytosol,7.148354e-06,15.0,7.148354e-06,-0.07141402,-0.24160999
Synthesis of IPs in the ER lumen,0.0,1.0,0.0,-0.075588435,0.39483184
Synthesis of IPs in the nucleus,4.340206e-08,3.0,4.340206e-08,-0.07556308,0.30348474
Synthesis of Ketone Bodies,1.781142e-08,4.0,1.781142e-08,-0.075578034,0.25779057
Synthesis of Leukotrienes (LT) and Eoxins (EX),1.3515602e-05,5.0,1.3515602e-05,-0.06769575,0.21799934
Synthesis of Lipoxins (LX),3.0906997e-09,3.0,3.0906997e-09,-0.07558663,0.30346715
Synthesis of PA,6.621225e-06,15.0,6.621225e-06,-0.071721844,-0.24184008
Synthesis of PC,1.6798906e-06,16.0,1.6798906e-06,-0.07460743,-0.28967997
Synthesis of PE,7.257594e-07,9.0,7.257594e-07,-0.07516461,0.029684583
Synthesis of PG,6.9266052e-06,7.0,6.9266052e-06,-0.071543515,0.12375725
Synthesis of PI,1.0746915e-07,3.0,1.0746915e-07,-0.07552568,0.30351272
Synthesis of PIPs at the ER membrane,4.0804316e-06,6.0,4.0804316e-06,-0.07320559,0.1681979
Synthesis of PIPs at the Golgi membrane,2.3506068e-06,12.0,2.3506068e-06,-0.074215755,-0.10665519
Synthesis of PIPs at the early endosome membrane,3.5725302e-06,14.0,3.5725302e-06,-0.07350219,-0.19748785
Synthesis of PIPs at the late endosome membrane,4.852255e-07,9.0,4.852255e-07,-0.07530508,0.029579585
Synthesis of PIPs at the plasma membrane,7.775577e-06,39.0,7.775577e-06,-0.07104774,-1.3377283
Synthesis of PIPs in the nucleus,4.039987e-08,4.0,4.039987e-08,-0.07556484,0.2578004
Synthesis of PS,0.0,1.0,0.0,-0.075588435,0.39483184
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),3.4018376e-07,5.0,3.4018376e-07,-0.07538978,0.21224827
Synthesis of active ubiquitin: roles of E1 and E2 enzymes,1.2843624e-05,22.0,1.2843624e-05,-0.06808816,-0.558905
Synthesis of bile acids and bile salts,9.806511e-06,7.0,9.806511e-06,-0.06986174,0.12501432
Synthesis of diphthamide-EEF2,4.5533598e-06,7.0,4.5533598e-06,-0.07292941,0.12272132
Synthesis of dolichyl-phosphate mannose,6.7777773e-07,2.0,6.7777773e-07,-0.07519263,0.34944466
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET),0.0,1.0,0.0,-0.075588435,0.39483184
Synthesis of glycosylphosphatidylinositol (GPI),6.37476e-05,12.0,6.37476e-05,-0.038361847,-0.07985548
Synthesis of pyrophosphates in the cytosol,8.014846e-10,2.0,8.014846e-10,-0.075587966,0.34914917
Synthesis of very long-chain fatty acyl-CoAs,9.711367e-08,13.0,9.711367e-08,-0.07553172,-0.15332183
Synthesis of wybutosine at G37 of tRNA(Phe),2.121833e-10,2.0,2.121833e-10,-0.07558831,0.3491489
"Synthesis, secretion, and deacylation of Ghrelin",7.419197e-06,6.0,7.419197e-06,-0.071255855,0.16965526
"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",9.567963e-05,7.0,9.567963e-05,-0.01971455,0.16249783
"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)",7.515112e-08,7.0,7.515112e-08,-0.07554455,0.1207666
T41 mutants of beta-catenin aren't phosphorylated,4.168078e-08,11.0,4.168078e-08,-0.075564094,-0.061980028
TAK1 activates NFkB by phosphorylation and activation of IKKs complex,5.4634947e-06,17.0,5.4634947e-06,-0.07239792,-0.33371145
"TALDO1 deficiency: failed conversion of  Fru(6)P, E4P to SH7P, GA3P",0.0,1.0,0.0,-0.075588435,0.39483184
"TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P",0.0,1.0,0.0,-0.075588435,0.39483184
TBC/RABGAPs,0.000101108824,29.0,0.000101108824,-0.01654407,-0.8401584
TCF7L2 mutants don't bind CTBP,4.588882e-12,3.0,4.588882e-12,-0.075588435,0.30346578
"TET1,2,3 and TDG demethylate DNA",1.8055673e-08,3.0,1.8055673e-08,-0.075577885,0.30347368
TFAP2 (AP-2) family regulates transcription of cell cycle factors,8.2550405e-06,4.0,8.2550405e-06,-0.07076775,0.2613861
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,6.5476333e-06,6.0,6.5476333e-06,-0.07176482,0.16927484
TFAP2 (AP-2) family regulates transcription of other transcription factors,0.0,1.0,0.0,-0.075588435,0.39483184
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation,1.7449833e-09,3.0,1.7449833e-09,-0.075587414,0.30346656
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),1.771787e-06,11.0,1.771787e-06,-0.074553765,-0.061224837
TGFBR1 KD Mutants in Cancer,3.9193657e-09,5.0,3.9193657e-09,-0.07558615,0.2121015
TGFBR1 LBD Mutants in Cancer,3.4687368e-08,3.0,3.4687368e-08,-0.07556818,0.30348092
TGFBR2 Kinase Domain Mutants in Cancer,8.568786e-12,3.0,8.568786e-12,-0.07558843,0.3034658
TGFBR2 MSI Frameshift Mutants in Cancer,1.4314224e-11,2.0,1.4314224e-11,-0.07558843,0.3491488
TICAM1 deficiency - HSE,0.0,1.0,0.0,-0.075588435,0.39483184
"TICAM1, RIP1-mediated IKK complex recruitment ",2.4557645e-05,13.0,2.4557645e-05,-0.061247543,-0.14264484
"TICAM1,TRAF6-dependent induction of TAK1 complex",4.9664046e-05,10.0,4.9664046e-05,-0.0465862,0.0053630746
TICAM1-dependent activation of IRF3/IRF7,1.0598674e-07,9.0,1.0598674e-07,-0.07552654,0.029414047
TLR3 deficiency - HSE,0.0,1.0,0.0,-0.075588435,0.39483184
TLR3-mediated TICAM1-dependent programmed cell death,4.8870365e-06,5.0,4.8870365e-06,-0.07273456,0.21423298
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,1.8169789e-10,8.0,1.8169789e-10,-0.07558833,0.075050876
TNFR1-induced NFkappaB signaling pathway,8.7494067e-07,12.0,8.7494067e-07,-0.0750775,-0.10729931
TNFR1-induced proapoptotic signaling,5.2649587e-09,4.0,5.2649587e-09,-0.07558536,0.25778508
TNFR1-mediated ceramide production,8.794857e-07,2.0,8.794857e-07,-0.07507484,0.34953272
TNFs bind their physiological receptors,8.199494e-07,5.0,8.199494e-07,-0.07510961,0.2124577
TP53 Regulates Metabolic Genes,0.0003967564,49.0,0.0003967564,0.15610479,-1.6247687
TP53 Regulates Transcription of Cell Cycle Genes,0.00029795422,24.0,0.00029795422,0.098407425,-0.5258206
TP53 Regulates Transcription of Cell Death Genes,6.405425e-05,31.0,6.405425e-05,-0.038182773,-0.94769865
TP53 Regulates Transcription of DNA Repair Genes,6.8851805e-05,45.0,6.8851805e-05,-0.035381153,-1.5851666
TRAF3 deficiency - HSE,1.2013601e-09,2.0,1.2013601e-09,-0.07558773,0.34914935
TRAF3-dependent IRF activation pathway,0.0031559237,12.0,0.0031559237,1.7673714,1.2698754
TRAF6 mediated IRF7 activation,0.00076816767,13.0,0.00076816767,0.37299725,0.18193997
TRAF6 mediated NF-kB activation,3.0019188e-05,14.0,3.0019188e-05,-0.058058172,-0.18594387
TRAIL  signaling,7.106486e-08,7.0,7.106486e-08,-0.07554693,0.12076482
TRP channels,8.287774e-05,4.0,8.287774e-05,-0.027190447,0.2939588
TWIK related potassium channel (TREK),0.0,1.0,0.0,-0.075588435,0.39483184
TWIK-related alkaline pH activated K+ channel (TALK),0.0,1.0,0.0,-0.075588435,0.39483184
TWIK-related spinal cord K+ channel (TRESK),0.0,1.0,0.0,-0.075588435,0.39483184
TWIK-releated acid-sensitive K+ channel (TASK),0.0,1.0,0.0,-0.075588435,0.39483184
TYSND1 cleaves peroxisomal proteins,2.7390213e-05,6.0,2.7390213e-05,-0.059593413,0.17837258
Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK),8.0935564e-08,3.0,8.0935564e-08,-0.07554117,0.3035011
Tandem pore domain halothane-inhibited K+ channel (THIK),0.0,1.0,0.0,-0.075588435,0.39483184
Telomere C-strand (Lagging Strand) Synthesis,3.6461824e-07,17.0,3.6461824e-07,-0.07537551,-0.33593708
Telomere Extension By Telomerase,1.0627889e-08,2.0,1.0627889e-08,-0.07558223,0.34915343
Terminal pathway of complement,0.0,1.0,0.0,-0.075588435,0.39483184
Termination of O-glycan biosynthesis,0.0001563566,6.0,0.0001563566,0.01571889,0.23466624
Termination of translesion DNA synthesis,3.2850006e-05,20.0,3.2850006e-05,-0.056405067,-0.45880625
"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",1.3714397e-05,7.0,1.3714397e-05,-0.06757966,0.12672012
The AIM2 inflammasome,2.2303615e-07,2.0,2.2303615e-07,-0.075458184,0.34924614
The IPAF inflammasome,1.10121654e-07,3.0,1.10121654e-07,-0.07552412,0.30351385
The NLRP1 inflammasome,1.8134483e-07,3.0,1.8134483e-07,-0.07548253,0.30354497
The NLRP3 inflammasome,5.849612e-07,9.0,5.849612e-07,-0.07524683,0.029623123
The activation of arylsulfatases,8.06932e-06,6.0,8.06932e-06,-0.0708762,0.16993904
The fatty acid cycling model,0.0,1.0,0.0,-0.075588435,0.39483184
The proton buffering model,0.0,1.0,0.0,-0.075588435,0.39483184
The role of GTSE1 in G2/M progression after G2 checkpoint,5.034619e-06,35.0,5.034619e-06,-0.072648376,-1.1561927
The role of Nef in HIV-1 replication and disease pathogenesis,1.8728403e-07,22.0,1.8728403e-07,-0.07547907,-0.56442946
Threonine catabolism,8.747166e-05,3.0,8.747166e-05,-0.024507746,0.34164706
Thrombin signalling through proteinase activated receptors (PARs),3.192474e-06,19.0,3.192474e-06,-0.07372413,-0.42606872
Thromboxane signalling through TP receptor,7.034477e-10,14.0,7.034477e-10,-0.075588025,-0.19904694
Tie2 Signaling,1.6514113e-07,12.0,1.6514113e-07,-0.075492,-0.10760913
Tight junction interactions,2.3375364e-07,10.0,2.3375364e-07,-0.07545193,-0.016213184
Tolerance by Mtb to nitric oxide produced by macrophages,0.0,1.0,0.0,-0.075588435,0.39483184
Tolerance of reactive oxygen produced by macrophages,0.0,1.0,0.0,-0.075588435,0.39483184
Toxicity of botulinum toxin type A (BoNT/A),2.8333579e-08,2.0,2.8333579e-08,-0.07557189,0.34916118
Toxicity of botulinum toxin type B (BoNT/B),7.012743e-08,2.0,7.012743e-08,-0.07554748,0.34917942
Toxicity of botulinum toxin type C (BoNT/C),4.9657793e-09,3.0,4.9657793e-09,-0.07558554,0.30346796
Toxicity of botulinum toxin type D (BoNT/D),6.097414e-08,4.0,6.097414e-08,-0.07555283,0.2578094
Toxicity of botulinum toxin type E (BoNT/E),2.3755995e-09,2.0,2.3755995e-09,-0.07558705,0.34914985
Toxicity of botulinum toxin type F (BoNT/F),7.94916e-09,4.0,7.94916e-09,-0.07558379,0.25778627
Toxicity of botulinum toxin type G (BoNT/G),2.000946e-08,3.0,2.000946e-08,-0.075576745,0.30347452
Toxicity of tetanus toxin (TeNT),6.532088e-09,2.0,6.532088e-09,-0.07558462,0.34915167
Trafficking and processing of endosomal TLR,3.143291e-06,7.0,3.143291e-06,-0.07375285,0.122105844
Trafficking of AMPA receptors,9.699295e-07,14.0,9.699295e-07,-0.07502203,-0.19862387
Trafficking of myristoylated proteins to the cilium,0.00011525929,4.0,0.00011525929,-0.008280645,0.3080933
Transcription of E2F targets under negative control by DREAM complex,1.3586942e-05,11.0,1.3586942e-05,-0.06765409,-0.05606753
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1,0.00010192301,6.0,0.00010192301,-0.016068611,0.21090603
Transcriptional Regulation by E2F6,0.0023731128,22.0,0.0023731128,1.3102347,0.47134954
Transcriptional activation of mitochondrial biogenesis,7.577391e-06,19.0,7.577391e-06,-0.071163476,-0.42415473
Transcriptional regulation by small RNAs,0.0010467168,40.0,0.0010467168,0.53566116,-0.92991465
Transcriptional regulation of white adipocyte differentiation,3.4778935e-07,40.0,3.4778935e-07,-0.07538533,-1.3866534
Transfer of LPS from LBP carrier to CD14,0.0,1.0,0.0,-0.075588435,0.39483184
Transferrin endocytosis and recycling,2.2028291e-05,16.0,2.2028291e-05,-0.062724605,-0.28079793
Translesion Synthesis by POLH,6.602723e-07,12.0,6.602723e-07,-0.07520285,-0.10739301
Translesion synthesis by POLI,4.634928e-06,11.0,4.634928e-06,-0.07288178,-0.059975076
Translesion synthesis by POLK,4.377361e-05,11.0,4.377361e-05,-0.050026026,-0.042891096
Translesion synthesis by REV1,4.3263612e-06,11.0,4.3263612e-06,-0.07306197,-0.060109768
Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00027399158,34.0,0.00027399158,0.084414005,-0.9931103
Translocation of ZAP-70 to Immunological synapse,2.1460791e-07,3.0,2.1460791e-07,-0.07546311,0.30355948
Transport and synthesis of PAPS,0.001888531,4.0,0.001888531,1.0272541,1.0821242
Transport of Mature mRNA Derived from an Intronless Transcript,3.4639586e-07,11.0,3.4639586e-07,-0.07538615,-0.061847016
Transport of Mature mRNA derived from an Intron-Containing Transcript,4.750755e-05,59.0,4.750755e-05,-0.047845524,-2.2340453
Transport of Ribonucleoproteins into the Host Nucleus,9.671116e-11,3.0,9.671116e-11,-0.075588375,0.30346584
Transport of fatty acids,1.3936206e-07,3.0,1.3936206e-07,-0.07550705,0.30352664
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus,0.0,1.0,0.0,-0.075588435,0.39483184
Transport of glycerol from adipocytes to the liver by Aquaporins,0.0,1.0,0.0,-0.075588435,0.39483184
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,9.054174e-09,2.0,9.054174e-09,-0.075583145,0.34915277
Transport of nucleotide sugars,1.3938285e-07,8.0,1.3938285e-07,-0.07550704,0.075111635
Transport of organic anions,2.820306e-06,4.0,2.820306e-06,-0.07394146,0.25901383
Transport of the SLBP Dependant Mature mRNA,7.341009e-07,6.0,7.341009e-07,-0.07515974,0.16673721
Transport of the SLBP independent Mature mRNA,1.6690686e-08,6.0,1.6690686e-08,-0.07557868,0.16642407
Triglyceride biosynthesis,5.0145704e-06,7.0,5.0145704e-06,-0.07266008,0.12292265
Triglyceride catabolism,2.771902e-07,10.0,2.771902e-07,-0.07542656,-0.016194224
"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",1.3365321e-05,11.0,1.3365321e-05,-0.067783505,-0.05616427
Truncations of AMER1 destabilize the destruction complex,1.7849923e-06,10.0,1.7849923e-06,-0.074546054,-0.015536066
Tryptophan catabolism,1.4991494e-06,6.0,1.4991494e-06,-0.07471298,0.16707116
Type I hemidesmosome assembly,1.7432446e-06,4.0,1.7432446e-06,-0.07457043,0.2585437
Type II Na+/Pi cotransporters,9.254773e-08,2.0,9.254773e-08,-0.07553439,0.34918922
UCH proteinases,0.00011905493,61.0,0.00011905493,-0.0060641104,-2.2941809
UNC93B1 deficiency - HSE,0.0,1.0,0.0,-0.075588435,0.39483184
Ub-specific processing proteases,0.00019030919,114.0,1.6693789e-06,-0.07461356,-4.684278
Ubiquinol biosynthesis,3.0370338e-06,5.0,3.0370338e-06,-0.073814906,0.21342546
Ubiquitin-dependent degradation of Cyclin D1,3.0545013e-06,33.0,3.0545013e-06,-0.0738047,-1.065691
"Unblocking of NMDA receptor, glutamate binding and activation",2.646617e-06,6.0,2.646617e-06,-0.074042894,0.16757204
Unwinding of DNA,9.927458e-11,9.0,9.927458e-11,-0.075588375,0.029367832
Uptake and function of anthrax toxins,5.72598e-09,7.0,5.72598e-09,-0.07558509,0.1207363
Uptake and function of diphtheria toxin,4.1105337e-09,3.0,4.1105337e-09,-0.075586036,0.3034676
Urea cycle,4.0135514e-05,2.0,4.0135514e-05,-0.05215056,0.36666793
Utilization of Ketone Bodies,5.157175e-13,3.0,5.157175e-13,-0.075588435,0.30346578
VEGF binds to VEGFR leading to receptor dimerization,6.40018e-07,3.0,6.40018e-07,-0.07521468,0.30374518
VEGFR2 mediated cell proliferation,1.6823423e-08,12.0,1.6823423e-08,-0.07557861,-0.107673876
VEGFR2 mediated vascular permeability,2.4928344e-09,19.0,2.4928344e-09,-0.07558698,-0.42746115
VLDL assembly,0.0,1.0,0.0,-0.075588435,0.39483184
VLDL clearance,4.3159207e-07,2.0,4.3159207e-07,-0.0753364,0.3493372
VLDLR internalisation and degradation,1.3435963e-05,7.0,1.3435963e-05,-0.06774225,0.12659858
Variant SLC6A14 may confer susceptibility towards obesity,0.0,1.0,0.0,-0.075588435,0.39483184
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.075588435,0.39483184
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.075588435,0.39483184
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.075588435,0.39483184
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.075588435,0.39483184
Vasopressin regulates renal water homeostasis via Aquaporins,0.00013856194,20.0,0.00013856194,0.005327367,-0.41266313
Vif-mediated degradation of APOBEC3G,9.015258e-09,33.0,9.015258e-09,-0.07558317,-1.0670203
Virus Assembly and Release,0.0,1.0,0.0,-0.075588435,0.39483184
Vitamin B1 (thiamin) metabolism,2.9254088e-05,4.0,2.9254088e-05,-0.05850497,0.27055216
Vitamin B2 (riboflavin) metabolism,4.1433196e-08,4.0,4.1433196e-08,-0.075564235,0.25780088
Vitamin C (ascorbate) metabolism,4.4585618e-06,4.0,4.4585618e-06,-0.07298477,0.25972894
Vitamin D (calciferol) metabolism,4.017048e-06,7.0,4.017048e-06,-0.073242605,0.12248723
Vitamin E,0.0,1.0,0.0,-0.075588435,0.39483184
Vitamins,2.135829e-06,2.0,2.135829e-06,-0.07434118,0.3500811
Vitamins B6 activation to pyridoxal phosphate,2.464736e-08,2.0,2.464736e-08,-0.07557404,0.34915957
Voltage gated Potassium channels,3.601898e-07,11.0,3.601898e-07,-0.07537809,-0.061840996
Vpu mediated degradation of CD4,2.7485976e-07,32.0,2.7485976e-07,-0.07542793,-1.0212213
VxPx cargo-targeting to cilium,1.5542111e-05,16.0,1.5542111e-05,-0.06651233,-0.28362915
WNT ligand biogenesis and trafficking,9.155383e-08,7.0,9.155383e-08,-0.07553496,0.120773755
WNT ligand secretion is abrogated by the PORCN inhibitor LGK974,0.0,1.0,0.0,-0.075588435,0.39483184
WNT mediated activation of DVL,3.409952e-06,6.0,3.409952e-06,-0.073597126,0.16790523
"WNT5A-dependent internalization of FZD2, FZD5 and ROR2",9.3045465e-08,3.0,9.3045465e-08,-0.0755341,0.3035064
WNT5A-dependent internalization of FZD4,1.763124e-07,9.0,1.763124e-07,-0.075485475,0.02944475
Wax biosynthesis,9.817573e-08,3.0,9.817573e-08,-0.075531095,0.30350867
"XAV939 inhibits tankyrase, stabilizing AXIN",6.6899425e-08,2.0,6.6899425e-08,-0.07554937,0.34917802
XBP1(S) activates chaperone genes,5.204592e-06,31.0,5.204592e-06,-0.07254911,-0.97338647
Xenobiotics,0.0,1.0,0.0,-0.075588435,0.39483184
YAP1- and WWTR1 (TAZ)-stimulated gene expression,1.0136221e-06,4.0,1.0136221e-06,-0.07499651,0.25822523
Zinc transporters,7.825e-06,8.0,7.825e-06,-0.07101888,0.0784664
alpha-linolenic acid (ALA) metabolism,1.1590321e-06,8.0,1.1590321e-06,-0.074911594,0.07555671
c-src mediated regulation of Cx43 function and closure of gap junctions,5.9538884e-06,3.0,5.9538884e-06,-0.07211155,0.30606467
cGMP effects,8.185939e-08,3.0,8.185939e-08,-0.07554063,0.30350152
eNOS activation,6.0097676e-08,7.0,6.0097676e-08,-0.075553335,0.12076003
mRNA 3'-end processing,4.0388924e-05,46.0,4.0388924e-05,-0.05200257,-1.6432737
mRNA Capping,4.6317624e-07,23.0,4.6317624e-07,-0.07531796,-0.6099921
mRNA Splicing - Major Pathway,0.0029548726,133.0,2.2217087e-05,-0.06261436,-4.3455267
mRNA Splicing - Minor Pathway,0.00013838914,38.0,0.00013838914,0.005226455,-1.2350326
mRNA decay by 3' to 5' exoribonuclease,0.0001372812,14.0,0.0001372812,0.0045794537,-0.13912416
mRNA decay by 5' to 3' exoribonuclease,4.0247023e-06,12.0,4.0247023e-06,-0.073238134,-0.10592444
mTORC1-mediated signalling,5.0294506e-07,12.0,5.0294506e-07,-0.07529473,-0.10746168
mitochondrial fatty acid beta-oxidation of saturated fatty acids,3.827563e-09,7.0,3.827563e-09,-0.0755862,0.12073546
mitochondrial fatty acid beta-oxidation of unsaturated fatty acids,6.154307e-10,2.0,6.154307e-10,-0.07558808,0.34914908
p130Cas linkage to MAPK signaling for integrins,2.103951e-06,8.0,2.103951e-06,-0.0743598,0.07596917
p53-Dependent G1 DNA Damage Response,1.7842982e-05,39.0,1.7842982e-05,-0.06516869,-1.3333338
p53-Independent DNA Damage Response,3.5580738e-06,32.0,3.5580738e-06,-0.07351063,-1.0197881
p75NTR negatively regulates cell cycle via SC1,3.5857047e-07,5.0,3.5857047e-07,-0.07537904,0.21225631
p75NTR recruits signalling complexes,1.5446093e-07,10.0,1.5446093e-07,-0.07549824,-0.0162478
rRNA modification in the mitochondrion,1.3688805e-07,4.0,1.3688805e-07,-0.07550849,0.25784254
rRNA modification in the nucleus and cytosol,0.000206167,38.0,0.000206167,0.044806585,-1.2054477
snRNP Assembly,4.6009044e-10,12.0,4.6009044e-10,-0.07558816,-0.10768101
tRNA modification in the mitochondrion,3.410569e-07,6.0,3.410569e-07,-0.075389266,0.16656566
tRNA processing in the mitochondrion,4.6220178e-10,2.0,4.6220178e-10,-0.07558816,0.34914902
tRNA processing in the nucleus,3.889864e-06,39.0,3.889864e-06,-0.07331688,-1.3394244
via Dependence Receptors in the absence of ligand,2.5057545e-09,9.0,2.5057545e-09,-0.075586975,0.02936888
